Curriculum Vitae

Peter W. F. Wilson, M.D.

Work VA Office
Dir. Epidemiology & Genomic Medicine
Atlanta VAMC
Room 5A140
1670 Clairmont Rd
Atlanta, GA 30022
peter.wilson@va.gov
(404) 321-6111 x6028 Voice

Work Emory Office
Emory Clinical Cardiovascular
Research Institute
1462 Clifton Rd
Room 505
Atlanta, GA 30322
(404) 727-6854 Voice
(866) 434-1997 Fax
peter.wf.wilson@emory.edu

(b) (6)

(b) (6)

Education and Certification
a) B.S. Yale College, 1970
b) M.D. Univ. of Texas Medical School at San Antonio, 1974
c) Diplomate of American Board of Internal Medicine 1977, Advanced Achievement in Internal Medicine 1987
d) Certified in Endocrinology and Metabolism, American Board of Internal Medicine 1981
e) Licensed to practice medicine in Maryland 1978, Massachusetts 1983, South Carolina 2003, Connecticut 2008, Georgia 2008
f) Special Purpose Examination (SPEX) certified 2004.

Related to reference materials for spectroscopy. http://www.spex.com/

Postgraduate Medical Training
a) Medical Internship, Duke Medical Center, 1974-5
b) Medical Jr. Assistant Residency, Duke Medical Center, 1975-6
c) Clinical Endocrinology Fellowship, Duke Medical Center, 1976-7
d) Medical Sr. Assistant Residency, Duke Medical Center, 1977-8
e) Staff Associate in Epidemiology, National Heart, Lung, and Blood Institute, Bethesda, MD 1978-80

Postgraduate Medical Employment
a) Medical Officer in Clinical and Genetic Epidemiology Section, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD 1980-1983 and Framingham, MA 1983-1999
b) Assistant Professor of Medicine, Uniformed Services University of the Health Sciences, 1982-1983
c) Temporary Adviser to the World Health Organization for Multinational Study of Vascular Disease in Diabetes, 1981
d) Director of Laboratories, Framingham Heart Study, Framingham, MA 1983-
e) Lecturer in Preventive Medicine and Epidemiology, Harvard Medical School, 1984-1995
f) Clinical Associate Professor of Medicine, Tufts University School of Medicine 1987-1999
g) Adjunct Assistant Professor of Medicine, Baylor College of Medicine, 1991-1992
h) Associate Professor of Medicine, Boston University School of Medicine 1994-1999
i) Professor of Medicine, Boston University School of Medicine 2000-2003
j) Program Director, General Clinical Research Center, Medical University of South Carolina 2003-2005
l) Professor of Medicine, Medical University of South Carolina 2003-2006

m) Vice Chair of Medicine (Research), Medical University of South Carolina 2005-2006
n) Professor of Medicine (Cardiology Section), Professor of Public Health (Global Health, Epidemiology), Emory University, Atlanta, GA 2006-
o) Director of Epidemiology and Genomic Medicine, Atlanta VAMC, Atlanta, GA 2006-

Postgraduate Medical Education
a) Epidemiology 1, Johns Hopkins School of Public Health, 1978
b) Epidemiology Summer session, Univ. of Minnesota, 1979 taking courses in cardiovascular epidemiology, genetics and epidemiology, and advanced statistical techniques
c) Epidemiology 2, Johns Hopkins School of Public Health, 1980
d) Short Course in Mammalian and Human Genetics, Bar Harbor, ME, 1980
e) Fellow at 14th International Ten Day Course-Cardiovascular Epidemiology, Heidelberg, W. Germany, 1981

Honors and Awards
a) Pauerstein Merit Scholarship Award by Medical School faculty for performance during third year of medical school (1973) b) Mosby Scholarship Book Award for top five ranking students during fourth year of medical school (1974) c) Alpha Omega Alpha honor medical society (1974) d) U.S. Public Health Service-- Citation Award (1989), Commendation Medal (1994) e) Who's Who in America (2000) f) ISI Highly Cited author [Clinical Medicine] for 1983-2003 g) Association of American Physicians (2005)

Professional Societies and Committees
Organizations: American Diabetes Association (Professional member 1986-), American College of Physicians (Member 1977-), American Heart Association--Prevention Conference (1988), Cholesterol Facts (1989), Special Study Section (1989), Massachusetts Cholesterol Task Force (1993-1999), Epidemiology and Prevention Council: Fellow (1985), AHA Spring Epidemiology Conference Program (Vice-Chair 2005-2006, Chair 2007-2008), AHA Nutrition and Physical Activity Council: Fellow (2007), Fall Sessions Program (Vice-Chair 2005-2006, Chair 2007-2008), AHA Expert Committee on Risk Factors and Subclinical Vascular Disease (Vice-chair 2006-2007, Chair 2008-2009), AHA Council of Committees (2007-2009), North American Association for the Study of Obesity (Fellow 2003), American Society Preventive Cardiology (Secretary 2006-2008, President 2008-2010), ACC/AHA 2013 Cholesterol Guideline Committee, ACC/AHA 2013 Risk Assessment Working Group

Editorial Boards: Atherosclerosis, Thrombosis, and Vascular Biology(1999–2002), American Journal of Cardiology(2000-2002), Current Opinion in Cardiology(2001-2002), Journal of Clinical Endocrinology and Metabolism (2006-), Journal of Clinical Lipidology (2007-), Endocrine Today (2007-)

Licensure
Massachusetts (#56404), South Carolina (#26554), Connecticut (#047076), Georgia (#61875)

References
Author or co-author of more than 550 scientific articles, 4 books

Bibliography

1 Eisenbarth G, **Wilson P**, Ward F, Lebovitz HE: HLA type and occurrence of disease in familial polyglandular failure. N Engl J Med 1978; 298: 92-94

2 **Wilson PW**, Easley RS, Bolander FF, Hammond C: Evidence for a hypothalamic defect in Septo-Optic Dysplasia. Arch Intern Med 1978; 138: 1276-1277

3 **Wilson PW**, Berry WR, Rosse WF: Splenectomy in sickle-cell disease (letter) Ann Intern Med 1979; 91: 320

4 Eisenbarth GS, **Wilson PW**, Ward F, Buckley C, Lebovitz HE: The Polyglandular Failure Syndrome: Disease inheritance, HLA type and immune function. Studies in patients and families. Ann Intern Med 1979; 91: 528-533

5 **Wilson PW**: Factors associated with the prevalence of CHD in young men. The Framingham Offspring Study. ACCEL Tapes 1980; 12:1

6 **Wilson PW**, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB: Prevalence of coronary heart disease in the Framingham Offspring Study. The role of lipoprotein cholesterols. Am J Cardiol 1980; 46: 649-654

7 Garrison RJ, **Wilson PW**, Castelli WP, Feinleib, Kannel WB, McNamara PM: Obesity and lipoprotein cholesterol in the Framingham Offspring Study. Metabolism 1980; 29: 1053-1060

8 **Wilson PW**, Buckley CE, Eisenbarth GS: Disordered immunoregulation in patients with Polyglandular Failure. J Clin Endo and Metab 1981; 52: 284-288

9 **Wilson PW**, McGee DL, Kannel WB: Obesity, very low density lipoproteins, and glucose intolerance: The Framingham Study. Am J Epidemiol 1981; 114: 697-704

10 **Wilson PW**, Abbott RD, Garrison RJ, Castelli WP: Estimation of very low density lipoprotein cholesterol from data on triglyceride concentration in plasma. Clin Chem 1981; 27: 2008-2010

11 Havlik RJ, **Wilson PW**, Garrison RJ, Feinleib M: Epidemiology of lipoproteins and the decline in coronary heart disease mortality. in Lipoproteins and Coronary Atherosclerosis eds. G. Noseda, C. Fragiacomo, R. Fumagalli, and R. Paoletti (1982) Elsevier Biomedical Press B.V. pp 61-68

12 Abbott RD, Garrison RJ, **Wilson PW**, Castelli WP: Coronary heart disease risk. The importance of joint relationships among cholesterol levels in individual lipoprotein classes. Prev Med 1982; 11: 131-141

13 **Wilson PWF**, Savage DD, Castelli WP, Garrison RJ, Donahue RP, Feinleib M: HDL-Cholesterol in a sample of black adults: The Framingham Minority Study. Metabolism 1983; 32: 328-332

14 Abbott RD, Garrison RJ, **Wilson PWF**, Epstein FH, Castelli WP, Feinleib M, LaRue CL: The joint distribution of lipoprotein cholesterol classes: The Framingham Study. Arteriosclerosis 1983; 3: 261-272

15 **Wilson PWF**, Garrison RJ, Abbott RD, Castelli WP: Factors associated with lipoprotein cholesterol levels: The Framingham Study. Arteriosclerosis 1983; 3: 273-281

16 Savage DD, Devereux RB, Donahue R, Joiner G, Anderson SJ, Rosen RA, **Wilson P**, Kramer R, Brown T, Garrison R, Castelli WP, Feinleib M: Mitral valve prolapse in blacks. J Natl Med Assoc 1982; 74: 895-900

17 Hoeg JM, Schaefer EJ, Romano CA, Bou E, Pikus AM, Zech LA, Bailey KR, Gregg RE, **Wilson PWF**, Sprecher DL, Grimes AM, Sebring NG, Ayres EJ, Jahn CE, Brewer Jr HB: Neomycin and plasma lipoproteins in type II hyperlipoproteinemia. Clin Pharm and Ther 1984; 36: 555-565

18 Kannel WB, **Wilson P**, Blair SN: Epidemiological needs in assessment of the role of physical activity and fitness in development of cardiovascular disease Amer Heart J. 1985; 109: 875-885

19 **Wilson PWF**, Zech LA, Gregg RE, Schaefer EJ, Hoeg JM, Brewer Jr HB: Estimation of VLDL-Cholesterol in Hyperlipidemia. Clin Chim Acta 1985; 151: 285-291

20 **Wilson PWF**, Garrison RJ, Castelli WP: Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity: The Framingham Study. N Engl J Med 1985; 313: 1038-1043

21 **Wilson PWF**, Kannel WB, Anderson KM: Lipids, glucose intolerance and vascular disease: The Framingham Study Karger monographs on Atherosclerosis, Vol 13. Dyslipoproteinemias and diabetes. pp 1-11, (Karger, Basel 1985)

22 Grab B, Grabauskas V, Jarrett RJ, Keen H, Teuscher A, **Wilson PWF**: Prevalence of small vessel and large vessel disease in diabetic patients from fourteen centres: The World Health Organization Multinational Study of Vascular Disease in Diabetes. Diabetologia 1985; 28: 615-640

23 Ordovas JM, Schaefer EJ, Salem D, Ward R, Glueck CJ, Vergani C, **Wilson PWF**, Karathanasis SK: Apolipoprotein A-I gene polymorphism in the 3' flanking region associated with familial hypoalphalipoproteinemia and premature coronary artery disease. N Engl J Med 1986; 314: 671-677

24 **Wilson PWF**, Anderson KM, Kannel WB: The epidemiology of diabetes mellitus in the elderly: The Framingham Study. Amer J Med 1986; 80 (5A): 3-9

25 Kannel WB, Garrison RJ, **Wilson PWF**: Obesity and nutrition in the diabetic elderly. Amer J Med 1986; 80 (5A): 22-30

26 **Wilson PWF**, Paffenbarger Jr RS, Morris JN, Havlik RJ: Assessment methods for physical activity and physical fitness in population studies: Report of a NHLBI workshop. Amer Heart J 1986; 111: 1177-1192

27 **Wilson PWF**: The cholesterol-to-coronary-risk connection. Masters in Cardiology 1986; 3: 10-13

28 **Wilson PWF**, Garrison RJ, Castelli WP: Postmenopausal estrogen use and heart disease (letter) N Engl J Med 1986; 315; 135 and 1987; 316: 343

29 Castelli WP, Garrison RJ, **Wilson PWF**, Abbott RD, Kalousdian S, Kannel WB: Coronary heart disease incidence and lipoprotein cholesterol levels: The Framingham Study JAMA 1986; 256: 2835-2838

30 Ordovas JM, Litwack-Klein L, **Wilson PWF**, Schaefer EJ: Apolipoprotein E isoform phenotyping methodology and population frequency with identification of ApoE1 and ApoE5 Isoforms in the Framingham Offspring Study. J Lipid Res 1987; 28: 371-380

31 **Wilson PWF**, Castelli WP, Kannel WB: Cardiovascular risk prediction in adults: The Framingham Heart Study. Am J Cardiol 1987; 59: 91G-94G

32 Kiel DP, Felson D, Anderson JJ, **Wilson PWF**, Moskowitz MA: Postmenopausal estrogen use and hip fracture: The Framingham Study. N Engl J Med 1987; 317: 1169-1174

33 Anderson KM, **Wilson PWF**, Garrison RJ, Castelli WP: Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample: The Framingham Offspring Study. Atherosclerosis 1987; 68: 59-66

34 McNamara JR, Campos H, Ordovas JM, Peterson J, **Wilson PWF**, Schaefer EJ: Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arteriosclerosis 1987; 7: 483-490

35 Ordovas JM, Peterson JP, Santaniello P, Cohn JS, **Wilson PWF**, Schaefer EJ: Enzyme-linked immunosorbent assay for human plasma apolipoprotein B. J Lipid Res 1987; 28: 1216-1224

36 Teuscher A, Schnell H, **Wilson PWF**: Eight year incidence of diabetic retinopathy in 358 Swiss Diabetics. Diabetes Care 1988; 11: 246-251

37 Abbott RD, **Wilson PWF**, Kannel WB, Castelli WP: High density lipoprotein cholesterol, total cholesterol,and myocardial infarction: The Framingham Study. Arteriosclerosis 1988: 8: 207-211

38 Hiller R, Sperduto RD, Podgor MJ, Ferris FL III, **Wilson PWF**: Diabetic retinopathy and cardiovascular disease in Type II diabetics. The Framingham Heart Study and the Framingham Eye Study. Amer J Epidemiol 1988; 128: 402-409

39 Campos H, McNamara JR, **Wilson PWF**, Ordovas JM, Schaefer EJ: Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endo Metab 1988; 67: 30-35

40 **Wilson PWF**, Abbott RD, Kannel WB, Castelli WP: High density lipoprotein cholesterol and mortality: The Framingham Study. Arteriosclerosis 1988; 8: 737-741

41 Abbott RD, Donahue RP, Kannel WB, **Wilson PWF**: The impact of diabetes on survival following myocardial infarction in men versus women: The Framingham Study. JAMA 1988; 260: 3456-3460
42 Dannenberg AL, Keller JB, **Wilson PWF**, Castelli WP: Leisure time physical activity in the Framingham Offspring Study. Description, seasonal variation, and risk factor correlates. Amer J Epid 1989; 129: 76-87
43 Abbott RD, Levy D, Kannel WB, Castelli WP, **Wilson PWF**, Garrison RJ, Stokes III J: Cardiovascular risk factors and graded treadmill exercise endurance in healthy adults: The Framingham Offspring Study. Am J Cardiol 1989; 63: 342-346
44 **Wilson PWF**, Garrison RJ, Kannel WB, McGee DL, Castelli WP: Is coffee consumption a contributor to cardiovascular disease: insights from the Framingham Study. Arch Intern Med 1989; 149: 1169-1172
45 Castelli WP, **Wilson PWF**, Levy D, Anderson K: Cardiovascular risk factors in the elderly. Am J Cardiol 1989; 63: 12H-19H
46 Felson DT, Anderson JJ, Hannan MT, Milton RC, **Wilson PWF**, Kiel DP: Impaired vision and hip fracture: The Framingham Study. J Amer Geriatric Soc 1989; 37: 495-500
47 **Wilson PWF**, Christiansen JC, Anderson KM, Kannel WB: Impact of national guidelines for cholesterol risk factor screening: The Framingham Offspring JAMA 1989; 262: 41-44 (letter JAMA 1989; 262: 2998)
48 Blair SN, Kannel WB, Kohn HW, Goodyear N, **Wilson PWF**: Surrogate measures of physical activity and physical fitness: Evidence for sedentary traits of resting tachycardia, obesity, and low vital capacity. Am J Epidemiol 1989; 129: 1145-56
49 Schaefer EJ, Moussa PB, **Wilson PWF**, McGee D, Dallal G, Castelli WP: Plasma lipoproteins in health octogenarians: Lack of reduced high density lipoprotein cholesterol levels. Results from the Framingham Heart Study. Metabolism 1989; 38: 293-296
50 **Wilson PWF**: Mild hypertension accompanied by other risk factors for coronary disease. Management Options in Cardiology. 1989; 1: 1-4
51 Breslow JL, Deeb S, Lalouel JM, LeBoeuf R, Schaefer EJ ,Tyroler HA, **Wilson P**, Young S: AHA Conference Report on Cholesterol: Workshop II: Genetic susceptibility to atherosclerosis. Circulation 1989; 80: 724-728
52 Fabsitz RR, Nam J-M, Gart J, Stunkard A, Price RA, **Wilson PWF**: HLA Associations with obesity. Human Heredity 1989; 39: 156-164
53 **Wilson PWF**: The epidemiology of hypercholesterolemia: a global perspective. Amer J Med 1989; 87 (suppl 4A): 5S-13S
54 Kaufman HW, McNamara JR, Anderson KM, **Wilson PWF**, Schaefer EJ: How reliably can compact chemistry analyzers measure lipids? JAMA 1990; 263: 1245-1249 (letters JAMA 1990; 264; 1101-1103)
55 McNamara JR, Cohn JS, **Wilson PWF**, Schaefer EJ: Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem 1990; 36: 36-42
56 Levy D, **Wilson PWF**, Anderson KM, Castelli WP: Stratifying the patient at risk from coronary disease: New insights from the Framingham Heart Study. Amer Heart J 1990; 119: 712-717
57 Gotto AM, LaRosa JC, Hunninghake D, Grundy SM, **Wilson PW**, Clarkson TB, Hay JW. The Cholesterol Facts: A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National, Heart, Lung, and Blood Institute. Circulation 1990; 81: 1721-1733
58 **Wilson PWF**: Importance of lipid fractions for coronary morbidity and mortality. in Cholesterol and Prevention Primaire: A qui s'adressent les régimes de prévention cardiovasculaire? Colloque International-Département Santé du CIDIL. Paris, France 1990, pp 73-80
59 Genest JJ, Ordovas JM, McNamara JR, Robbins AM, Meade T, Cohn SD, Salem DN, **Wilson PWF**, Masharani U, Frossard PM, Schaefer EJ: DNA polymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease. Atherosclerosis 1990; 82: 7-17

60 Donahue RP, Abbott RD, **Wilson PWF**: Effect of diuretic use on the development of diabetes mellitus. The Framingham Study. in Effects of Antihypertensive treatment on glucose metabolism. Thieme Medical Publishers 1990 (New York) pp 46-48
61 Jones MG, Anderson KM, **Wilson PW**, Kannel WB, Hindman NB, Wagner GS: Mortality after recognized myocardial infarction . The prognostic use of a QRS scoring system in the Framingham Study. Am J Cardiol 1990; 66: 546-550
62 **Wilson PWF**: High-density lipoprotein, low density lipoprotein and coronary artery disease. Am J Med 1990; 66: 7A-10A
63 Kiel DP, Felson DT, Hannan MT, Anderson JJ, **Wilson PWF**: Caffeine intake and the risk of hip fracture: The Framingham Study. Amer J Epidemiol 1990; 132: 675-684
64 Kannel WB, D'Agostino RB, **Wilson PWF**, Belanger AJ: Diabetes, fibrinogen and risk of cardiovascular disease. The Framingham experience. Amer Heart J 1990; 120: 672-676
65 **Wilson PWF**, Castelli WP: Coronary heart disease--The view from Framingham, in Coronary Risk Factors Revisited eds. Shepherd J, Packard CJ, McEwan SR, and Brownlie SM, Excerpta Medica (Amsterdam), 1989, pp 3-14
66 Anderson KM, Dumphy DC, **Wilson PWF**: Management of data quality in a long-term epidemiologic study: The Framingham Heart Study. in Data Quality Control: Theory and Pragmatics. eds Liepins GE and Uppuluri V.R.R., Marcel Dekker, New York, NY, 1990, pp 57-68
67 Anderson KM, **Wilson PWF**, Odell PM, Kannel WB: An updated coronary risk profile. a statement for health professionals. Circulation 1991; 83: 356-362
68 Anderson KM, Odell PM, **Wilson PWF**, Kannel WB: Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-298
69 **Wilson PWF**, Anderson KM, Castelli WP, Kannel WB: Twelve year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: The Framingham Offspring Study. Amer J Med 1991; 90: 11-16
70 **Wilson PWF**, Cupples LA, Kannel WB: Is hyperglycemia associated with cardiovascular disease? The Framingham Heart Study Amer Heart J 1991; 121: 586-590
71 **Wilson PWF**, Anderson KM: HDL cholesterol and triglycerides as risk factors for CHD, in Atherosclerosis and Cardiovascular Disease, 7th International Meeting eds Descovich GC, Gaddi A, Magri GL, Lenzi S. Kluwer Academic Publishers, Dordrecht, 1990, pp 609-615
72 Sawin CT, Geller A, Kaplan MM, Bacharach P, **Wilson PWF**, Hershman JM: Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism Arch Intern Med 1991; 151; 165-168
73 **Wilson PWF**, Anderson KM, Castelli WP: The impact of triglycerides on coronary heart disease. The Framingham Study. Atherosclerosis Reviews 1991; 22: 59-63
74 Kannel WB, **Wilson PWF**, Zhang T-J: The epidemiology of impaired glucose tolerance. Am Heart J 1991; 121: 1268-1273
75 Genest JJ Jr, Jenner JL, McNamara JR, Ordovas JM, Silberman SR, **Wilson PWF**, Schaefer EJ: Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease Am. J. Cardiol 1991; 67: 1039-1045
76 Campos H, **Wilson PWF**, Jimenez D, McNamara JR, Ordovas JM, Schaefer EJ: Differences in apolipoproteins and low-density lipoprotein subfractions in postmenopausal women on and off estrogen therapy: results from the Framingham Offspring Study. Metabolism 1990; 39: 1033-1038
77 Genest JJ, McNamara JR, Salem DN, **Wilson PWF**, Schaefer EJ, Malinow MR: Plasma homocyst(e)ine levels in men with premature coronary artery disease, JACC 1990; 16: 1114-1119
78 Galderisi M, Anderson KM, **Wilson PWF**, Levy D: Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study) Am. J. Cardiol 1991; 68: 85-89
79 Wong ND, **Wilson PWF**, Kannel WB: Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham Study Ann. Intern. Med. 1991; 115: 687-693

80 Genest JJ Jr, Bard JM, Fruchart J-C, Ordovas JM, **Wilson PWF**, Schaefer EJ: Plasma apolipoprotein A-I, A-II, B, E and CIII containing particles in men with premature coronary artery disease. Atherosclerosis 1991; 90: 149-157

81 Felson DT, Hannan MT, Naimark A, Berkeley J, Gordon G, **Wilson PWF**, Anderson J: Occupational physical demands, knee bending, and knee osteoarthritis: results from the Framingham Study. J. Rheumatol. 1991; 18: 1587-1592

82 Campos H, Willett WC, Peterson RM, Siles X, Bailey SM, **Wilson PWF**, Posner BM, Ordovas JM, Schaefer EJ. Nutrient intake comparisons between Framingham and rural and urban Puriscal, Costa Rica: associations with lipoproteins, apolipoproteins, and low density lipoprotein particle size. Arteriosclerosis and Thrombosis 1991; 11: 1089-1099

83 Castelli WP, Anderson K, **Wilson PWF**, Levy D: Lipids and risk of coronary heart disease: The Framingham Study. Ann. Epidemiol 1992; 2: 24-28

84 D'Agostino RB, Cobb JL, Wolf PA, **Wilson PWF**: Aspirin use and cardiovascular disease in women. JAMA (letter) 1992; 267: 364

85 Singer DE, Nathan DM, Anderson KM, **Wilson PWF**, Evans JC: Association of hemoglobin A1C with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41: 202-208

86 Kannel WB, Anderson K, **Wilson PWF**: White blood cell count and cardiovascular disease: insights from the Framingham Study JAMA 1992; 267: 1253-1256

87 Lamon-Fava S, Jimenez D, Christian JC, Fabsitz RR, Reed T, Carmelli D, Castelli WP, Ordovas JM, **Wilson PWF**, Schaefer EJ: The NHLBI Twin Study: Heritability of apolipoprotein A-I, B, and low density lipoprotein subclasses and concordance for lipoprotein (a). Atherosclerosis 1991; 91: 97-106

88 Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM **Wilson PWF**, Schaefer EJ: Low density lipoprotein particle size and coronary artery disease. Arteriosclerosis 1992; 12: 187-195

89 **Wilson PWF**, Kannel WB: Heterogeneity of so-called essential hypertension. Hypertension Index and Reviews 1992; 2: (No.5); 1-2

90 Haskell WL, Leon AS, Caspersen CJ, Froehlicher VF, Hagberg MJ, Harlan W, Holloszy JO, Regensteiner JG, Thompson PD, Washburn RA, **Wilson PWF**: Cardiovascular benefits and assessment of physical activity and physical fitness in adults. Medicine and Science in Sports and Exercise 1992; 24: S201-S220

91 **Wilson PWF**, Kannel WB: Epidemiology of hyperglycemia and atherosclerosis. in Hyperglycemia, Diabetes, and Vascular Disease, eds Ruderman, Williamson and Brownlee, Oxford Univ. Press (1992) pp 31-38

92 Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, **Wilson PWF**, Salem DN, Schaefer EJ: Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease JACC 1992; 19: 792-802

93 Civeira F, Genest J, Pocovi M, Salem DN, Herbert PN, **Wilson PWF**, Schaefer EJ, Ordovas JM: The MspI restriction fragment length polymorphism 3' to the apolipoprotein A-II gene: relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis 1992; 92: 165-176

94 Ordovas JM, Civeira F, Genest J Jr, Craig S, Robbins AH, Meade T, Pocovi M, Frossard PM, Masharani U, **Wilson PWF**, Salem DN, Ward RH, Schaefer EJ: Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. relationships with lipids, apolipoproteins, and premature coronary artery disease Atherosclerosis 1991; 87: 75-86

95 Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, **Wilson PWF**, Salem DN, Schaefer EJ: Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85: 2025-2033

96 Kannel WB, **Wilson PWF**: Efficacy of lipid profiles in predicting coronary disease. Am. Heart J 1992; 124: 768-774

97 Thompson GR, **Wilson PWF**: Coronary Risk Factors and Their Assessment. Science Press, London, 1992

98 Garrison RJ, Gold RS, **Wilson PWF**, Kannel WB: Educational attainment and coronary heart disease risk: The Framingham Offspring Study. Prev. Med. 1993; 22: 54-64
99 **Wilson PWF**, Kannel WB: Is baldness bad for the heart? (editorial) JAMA 1993; 269: 1035-1036
100 Roubenoff R, **Wilson PWF**: Advantage of knee height over height as an index of stature in expression of body composition in adults. Am J Clin Nutr 1993; 57: 609-613
101 **Wilson PWF**, Kannel WB: Hypercholesterolemia and coronary risk in the elderly: the Framingham Study. Am. J. Geriat. Cardiol. 1993; 2: 52-56
102 Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, **Wilson PWF**, Castelli WP, Schaefer EJ: Effects of age, gender, and menopausal status on plasma lipoprotein (a) levels: The Framingham Offspring Study Circulation 1993; 87: 1135-1141
103 Schaefer EJ, Genest JJ Jr, Ordovas JM, Salem DN, **Wilson PWF**: Familial lipoprotein disorders and premature coronary artery disease. Current Opinion in Lipidology 1993; 4: 288-298
104 Shively CA, Knox SE, Sherwin BB, Walsh BW, **Wilson PW**F: Sex steroids, psychosocial factors, and lipid metabolism. Metabolism 1993; 42 (supp 1): 16-24
105 Felson DT, Zhang Y, Hannan MT, Kiel DP, **Wilson PW**F, Anderson JJ: The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141-1146
106 Campos H, McNamara JR, Ordovas JM, Posner BM, **Wilson PW**F, Castelli WP, Schaefer EJ: LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler.Thromb. 1992; 12: 1410-1419
107 Posner BM, Cupples LA, Gagnon D, **Wilson PW**F, Chetwynd K, Felix D: Healthy People 2000. The rationale and potential efficacy of preventive nutrition in heart disease: the Framingham Study Arch.Intern.Med 1993; 153: 1549-1556
108 Vaziri SM, Evans JC, Larson MG, **Wilson PW**F: The impact of female hormone usage on the lipid profile: the Framingham Offspring Study Arch. Intern. Med 1993; 153: 2200-2206
109 Selhub J, Jacques PF, **Wilson PW**F, Rush D, Rosenberg IH: Vitamin status and intake as primary determinants of homocysteinemia in the elderly JAMA 1993; 270: 2693-2698
110 Lyu L-C, Shieh M-J, Ordovas JM, Lichtenstein AH, **Wilson PW**F, Schaefer EJ: Plasma lipoprotein and apolipoprotein levels in Taipei and Framingham. Arterioscler. Thromb. 1993; 13: 1429-1440
111 **Wilson PW**F, Evans JC: Coronary artery prediction. Amer J Hypertension 1993; 6: 309S-311S
112 **Wilson PW**F: Total Cardiovascular Risk in Hypertension Primer: The Essentials of High Blood Pressure. eds Izzo JL and Black HR. American Heart Association 1993 Chapter C17, pp 190-191
113 McNamara JR, Jenner JL, Li Z, **Wilson PW**F, Schaefer EJ: Change in LDL particle size is associated with change in plasma triglyceride concentration Arterioscler. Thromb. 1992; 12: 1284-1290
114 Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, **Wilson PW**F, Kelly-Hayes M,Wolf PA, Kreger BE, Milton RC, Kannel WB: Comorbidity and physical disability in the elderly: a disease- and task-specific comparison. Amer J Publ Hlth 1994; 84: 351-358
115 Kreger BE, D'Agostino RB, Odell P, **Wilson PW**F: Long-term intraindividual cholesterol variability: Natural course and adverse impact on morbidity and mortality-- The Framingham Study. Am Heart J. 1994; 127:1607-1614
116 **Wilson PW**F, Larson MG, Castelli WP: Triglycerides, HDL-C and coronary heart disease: a Framingham update on their interrelationships. Canadian J. Cardiology 1994: 10: 5B-9B
117 Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, **Wilson PW**F: Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 1994; 35: 779-792
118 Schaefer EJ, Lamon-Fava S, Johnson S, Ordovas JM, Schaefer MM, Castelli WP, **Wilson PW**F: Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels: Results from the Framingham Offspring Study Arterioscler. Thromb. 1994; 14: 1105-1113

119 **Wilson PW**F: Established risk factors and coronary heart disease: the Framingham Study Amer J. Hypertension 1994; 7: 7S-12S
120 The Framingham Offspring Eye Study Group. Familial aggregation of lens opacities: The Framingham Eye Study and the Framingham Offspring Eye Study
Am J Epidemiol 1994; 140: 555-564
121 Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, **Wilson PW**F, Benjamin EJ, D'Agostino RB: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331; 1249-1252
122 Lindenbaum J, Rosenberg IH, **Wilson PW**, Saha JR, Stabler SP, Allen RH: Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994; 60: 2-11
123 Bostom AG, Gagnon DR, Cupples LA, **Wilson PW**F, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP: A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study Circulation 1994; 90: 1688-1695
124 **Wilson PW**F, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ: Apolipoprotein E Alleles, Dyslipidemia, and Coronary Heart Disease: The Framingham Offspring Study. JAMA 1994; 272: 1666-1671
125 Kannam JP, Levy D, Larson M, **Wilson PW**F: Short stature and risk for mortality and cardiovascular disease events: the Framingham Heart Study. Circulation 1994; 90: 2241-2247
126 **Wilson PW**F, Anderson KM, Harris T, Kannel WB, Castelli WP: Determinants of change in total cholesterol and HDL-C with age: The Framingham Study. Journal of Gerontology: Medical Sciences 1994; 49: 252-257
127 **Wilson PW**F: Relation of high-density lipoprotein subfractions and apolipoprotein E isoforms to coronary disease. Clin Chem 1995; 41: 165-169
128 Garrison RJ, Sawin CT, **Wilson PW**F, Kannel WB: Plasma estradiol in premenopausal women: The Framingham Offspring Study. Journal of Women's Health 1995; 3: 435-443
129 Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, **Wilson PW**F: Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994; 35: 871-882
130 Lyu L-C, Shieh M-J, Posner BM, Ordovas JM, Dwyer JT, Lichtenstein AH, Cupples LA, Dallal GE, **Wilson PW**F, Schaefer EJ: Relationship between dietary intake, lipoproteins, and apolipoproteins in Taipei and Framingham. Am J Clin Nutr 1994; 60: 765-774
131 Rodriguez CR, Seman LJ, Ordovas JM, Jenner J, Genest JJ Jr, **Wilson PW**F, Schaefer EJ: Lipoprotein(a) and coronary heart disease. Chem Phys Lipids 1994; 67: 389-398
132 Selhub J, Jacques PF, Bostom AG, D'Agostino RB, **Wilson PW**F, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH: Association between plasma homocysteine and extracranial carotid stenosis. N Engl J Med 1995; 332: 286-291
133 Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, **Wilson PW**F, Levy D, Muller JE, Tofler GH: Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study Circulation 1995; 91:1952-1958
134 Kannel WB, **Wilson PW**F: Risk factors that attenuate the female coronary disease advantage Arch Intern Med 1995; 155: 57-61
135 **Wilson PW**F, Kannel WB: Hypertension, other risk factors, and the risk of cardiovascular disease. Chapter 7 in Hypertension: Physiology, Diagnosis, and Management. Second Edition, eds Laragh JH and Brenner BM. Raven Press, New York 1995, pp 99-114
136 Roubenoff R, Dallal GE, **Wilson PW**F: Predicting body fatness: the body mass index vs estimation by bioelectrical impedance. Am J Publ Hlth 1995; 85: 726-728

137 Li-Ching L, Posner BM, Shieh M-J, Lichtenstein AH, Cupples LA, Dwyer JT, **Wilson PW**F, Schaefer EJ: Cross-cultural comparisons between Taipei Chinese and Framingham Americans: dietary intakes, blood lipids and apolipoproteins. Asia Pacific J Clin Nutr 1994; 3: 119-125

138 Myers RH, Schaefer EJ, **Wilson PW**F, D'Agostino R, Bachman DL, Ordovas JM, Au R, Cobb JL, Wolf PA: Apolipoprotein E allele 4 is associated with dementia in the Framingham Study in Research Advances in Alzheimer's disease and Related Disorders eds Iqbal K, Mortimer JA, Winblad B, Wisniewski HM, Wiley & Sons 1995, pp 63-70

139 Kannel WB, **Wilson PW**F: An update on coronary risk factors. Med Clin N America 1995; 79: 951-971

140 **Wilson PW**F: Cholesterol screening: Once is not enough. (editorial) Archives of Internal Medicine Arch Intern Med 1995; 155: 2146-2147

141 Podgor MJ, Hiller R, Framingham Eye Studies Group: Associations of types of lens opacities betweeen and within eyes of individuals: an application of second-order generalized estimating equations. Statistics in Medicine 1996; 15: 145-156

142 Welty FK, Ordovas J, Schaefer EJ, **Wilson PW**F, Young SG: Identification and molecular analysis of two ApoB gene mutations causing low plasma cholesterol levels. Circulation 1995; 92: 2036-2040

143 Myers RH, Schaefer EJ, **Wilson PW**F, D'Agostino RB, Ordovas JM, Espino A, Au R, White RF, Knoefel JE, Cobb JL, McNulty KA, Wolf PA: Apolipoprotein E allele 4 is associated with dementia in the Framingham Study. Neurology. 1996; 46: 673-677

144 Lindpaintner K, Lee M, Larson MG, Rao VS, Pfeffer MA, Ordovas JM, et al. Absence of association or genetic linkage between the angiotensin- converting-enzyme gene and left ventricular mass. N Engl J Med 1996; 334:1023-1028

145 Meigs JB, Singer DE, Nathan DM, Cupples LA, **Wilson PW**F: Tracking of hemoglobin A_{1c} in the original cohort of the Framingham Heart Study J. Clin. Epidemiol 1996; 49: 411-417

146 Kannel WB, **Wilson PW**F: Homocysteine, folate, and vascular disease.(editorial) J Myocardial Ischemia 1996; 8: 60-63

147 Contois JH, McNamara JR, Lammi-Keefe CJ, **Wilson PW**F, Schaefer EJ: Reference Intervals for plasma apolipoprotein B as determined with a commercially available immunoturbidimetric Assay: Results from the Framingham Offspring Study Clin. Chem. 1996; 42: 515-523

148 Contois JH, McNamara JR, Lammi-Keefe CJ, **Wilson PW**F, Schaefer EJ: Reference intervals for plasma apolipoprotein A-I as Determined with a Commercially Available Immunoturbidimetric Assay: Results from the Framingham Offspring Study Clin. Chem 1996; 42: 507-514

149 **Wilson PW**F, Castelli WP: The Newer Coronary Risk Factors (chapter 10). Atlas of Heart Diseases ed E. Braunwald Volume X Atherosclerosis: Risk factors and treatment Brown,W.V. (Volume Editor) Mosby (St. Louis) 1996

150 **Wilson PW**F: Surrogate markers and prediction of cardiovascular disease (chapter 2) in Surrogate markers to assess efficacy of treatment in chronic liver disease. eds, Reichen R.E.. & Reichen J Kluwer 1996, pages 8-18

151 Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, **Wilson PW**F, Schaefer EJ, Castelli WP: Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 1996; 276: 544-548

152 McAlindon TE, Felson DT, Zhang Y, Hannan MT, Aliabadi P, Weissman B, Rush D, **Wilson PW**F, Jacques P:Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study Ann Intern Med 1996; 125: 353-359

153 Kannel WB, **Wilson PW**F: Update on hyperlipidemia in the elderly: Is this a risk factor for heart diease? Amer J Geriatric Cardiology 1996; 5: 9

154 **Wilson PW**F, Schaefer EJ, Larson MG, Ordovas JM: Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arteriosclerosis, Thrombosis and Vascular Biology 1996; 16: 1250-1255

155 Siegel RD, Cupples A, Schaefer EJ, **Wilson PW**F: Dyslipidemia and Diabetes: The Framingham Offspring Study. Metabolism 1996; 45: 1267-1272

156 Li Z, McNamara JR, Fruchart J-C, Luc G, Bard JM, Ordovas JM, **Wilson PW**F, Schaefer EJ: Effects of gender, age and menopausal status on plasma lipoprotein subspecies and particle sizes J Lipid Res 1996; 37: 1886-1896

157 Tucker KL, Mahnken B, **Wilson PW**F, Jacques P, Selhub J: Folate fortification of the food supply: potential benefits and risks to the elderly population JAMA 1996; 276: 1879-1885

158 Contois JH, Lammi-Keefe CJ, McNamara JR, Vogel S, **Wilson PW**F, Schaefer EJ: Plasma lipoprotein (a) distribution in the Framingham Offspring Study as determined with a commercially available immunoturbidimetric assay Clin Chim Acta 1996; 253:21-35

159 Lamon-Fava S, **Wilson PW**F, Schaefer EJ: Body mass index and coronary heart disease risk factors in men and women: The Framingham Offspring Study Arteriosclerosis, Thrombosis and Vascular Biology. 1996; 16: 1509-1515

160 Welty FK, Mittleman MA, **Wilson PW**F, Sutherland PA, Matheney TH, Lipinska I, Muller JE, Levy D, Tofler GH: Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham Offspring Study. Circulation 1997; 95: 825-830

161 Kannel WB, **Wilson PW**F: Comparison of risk profiles for cardiovascular events: Implications for prevention. Advances in Internal Medicine 1997; 42: 39-66

162 **Wilson PW**F, Kannel WB: Should we measure lipoprotein(a)? (editorial) Archives of Internal Medicine 1997; 157: 1161-1162

163 Kiel DP, Myers RH, Cupples LA, Kong XF, Zhu XH, Ordovas J, Schaefer EJ, Felson DT, Rush D, **Wilson PW**F, Eisman JA, Holick MF: The BsmI vitamin D receptor restriction fragment length polymorphism (bb) influences the effect of calcium intake on bone mineral density. J Bone and Mineral Research 1997; 12: 1049-1057

164 Murabito JM, D'Agostino RB, Silbershatz H, **Wilson PW**F: Intermittent Claudication: a risk profile from the Framingham Heart Study. Circulation 1997; 96: 44-49

165 Tucker K, Selhub J, **Wilson PW**F, Rosenberg I: Dietary intake pattern relates to plasma folate and homocysteine levels in the Framingham Heart Study. J Nutr 1996; 126: 3025-3031

166 Roubenoff R, Baumgartner RN, Kiel DP, Dallal GE, Hannnan MT, Economos CD, Stauber PM, **Wilson PW**F, Harris TB: Application of bioelectrical impedance analysis to elderly populations. J Gerontology A. Biol Sci Med Sci 1997; 52: M129-136

167 Kannel WB, **Wilson PW**F: Relevance of dyslipidemia in the elderly. ACC Current Journal Review 1996 (Sept); 14-15

168 **Wilson PW**F, Hoeg JM, D'Agostino RB, Belanger AM, Silbershatz H, O'Leary D, Wolf PA: Cumulative Effects of Serum Cholesterol, Blood Pressure and Cigarette Smoking on Carotid Stenosis. N Engl J Med 1997; 337: 516-522

169 Kauppila LI, Polak J, Cupples LA, Hannan MT, Kiel DP, **Wilson PW**F: New indices to classify location, severity, and progression of calcific lesions in the abdominal aorta: a 25 year follow-up study. Arteriosclerosis 1997; 132: 245-250

170 Elias PK, Elias MF, D'Agostino RB, Cupples LA, **Wilson PW**F, Silbershatz H, Wolf PA: NIDDM and blood pressure as independent risk factor for poor cognitive performance. Diabetes Care 1997; 20: 1388-1395

171 Kauppila LI, McAlindon T, Evans S, **Wilson PW**F, Kiel D, Felson DT: Disc degeneration/back pain and calcification of the abdominal aorta. Spine 1997; 22: 1642-1647

172 Hiller R, Sperduto RB, Podgor MJ, **Wilson PW**F, Ferris III FL, Colton T, D'Agostino RB, Roseman MJ, Stockman ME, Milton RC: Cigarette Smoking and the risk of development of lens opacities Arch Ophthalmol 1997; 115: 1113-1118

173 Meigs, JB, D'Agostino, RB, Wilson, PWF., Cupples, LA, Nathan, DM, and Singer, DE. Risk variable clustering in the insulin resistance syndrome: The Framingham Offspring Study. Diabetes 1997; 46:1594-1600

174 **Wilson PW**F: An epidemiologic perspective on hypertension, ischemic heart disease, and heart failure. Am J Cardiology 1997; 80 (9B): 3J-8J

175 Vogel S, Contois JH, Tucker KL, **Wilson PW**F, Schaefer EJ, Lammi-Keefe CJ: Plasma retinol and plasma and lipoprotein tocopherol and carotenoid concentrations in healthy elderly participants of the Framingham Heart Study Am J Clin Nutr 1997; 66: 950-958

176 Levy D, **Wilson PW**F: Atherosclerotic Cardiovascular Disease : An epidemiologic perspecitive in Textbook of Cardiovascular Medicine, (ed Topol E): Lippincott-Raven 1997, p 13-30

177 Krall EA, Dawson-Hughes B, Hannan MT, **Wilson PW**F, Kiel DP: Postmenopausal estrogen replacement and tooth retention. Am J Med 1997; 102: 536-542

178 **Wilson PW**F: Newer metabolic risk factors for heart disease: A brief review. Saudi Arabian Medical Journal 1998; 18: 439-446

179 Roubenoff R, Harris TB, Abad LW, **Wilson PW**F, Dallal GE, Dinarello CA: Monocyte cytokine production in an elderly population: Effect of age and inflammation. J Gerontology:Medical Sciences 1998; 53A: M20-M26

180 **Wilson PW**F: An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. Am J Cardiol 1997; 80(9B): 3J-8J

181 **Wilson PW**F, Kannel WB: Clustering of risk factors, obesity, and syndrome X. Nutrition in Clinical Care 1998; 1(suppl 1): 44-50

182 Kannel WB, **Wilson PW**F, Silbershatz H, D'Agostino RB: Epidemiology of risk factor clustering in elevated blood pressure in Multiple Risk Factors in Cardiovascular Disease (ed Gotto Jr AM et al), 1998, (Kluwer, Netherlands) pp 325-333

183 Fleming DJ, Jacques PF, Dallal GE, Tucker KL, **Wilson PW**F, Wood RJ: Dietary determinants of iron stores in a free-living elderly population: The Framingham Heart Study Am J Clin Nutr 1998; 67: 722-733

184 Meigs JB, Nathan DM, **Wilson PW**F, Cupples LA, Singer DE: Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: The Framingham Offspring Study. Ann Intern Med 1998; 128: 524-533

185 **Wilson PW**F, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847

186 Ordovas JM, Cupples LA, **Wilson PW**F, Lahoz C, Levy D, Otvos JD, McNamara JR, Gagne E, Hayden M, Schaefer EJ: Advances in cardiovascular risk prediction: new biochemical and genetic markers. in Atherosclerosis XI (ed B. Jacotot, D. Mathe, J-C Fruchart) Elsevier Press (Singapore) 1998, pp 425-431

187 **Wilson PW**F, D'Agostino RB, Kannel WB: Secular trends in cardiovascular risk factor levels: a Framingham perspective. in Atherosclerosis XI ed B. Jacotot, D. Mathe, J-C Fruchart. Elsevier Press (Singapore) 1998, pp 659- 664

188 Visser M, Kiel DP, Langlois J, Hannan M, Felson DT, **Wilson PW**F, Harris TB: Muscle mass and fat mass in relation to bone mineral density in very old men and women: the Framingham Heart Study. Applied Radiology and Isotopes 1998; 49: 745-747

189 McNamara, J.R., Shah, P.K., Nakajima, K., Cupples, L.A., Wilson, P.W., Ordovas, J.M., and Schaefer, E.J. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. Clinical Chemistry 1998; 44:1224-1232

190 Hiller R, Podgor MJ, Sperduto RD, Nowroozi L, **Wilson PW**F, D'Agostino RB, Colton T, Framingham Eye Studies Group: A longitudinal study of body mass index and lens opacities: The Framingham Studies Ophthalmology 1998; 105: 1244-1250

191 Visser M, Harris TB, Hannan MT, Roubenoff R, Felson DT, **Wilson PW**F, Kiel DP: Body fat and skeletal muscle mass in relation to physical disability in vbery old men and women of the Framingham Heart Study. J Gerontology 1998; 53A: M214-M221

192 Fraenkel L, Zhang Y, Chaisson C, Evans S, **Wilson PW**F, Felson DT: The association of estrogen replacement therapy and Raynaud's phenomenon in post-menopausal women. Annals of Internal Medicine 1998; 129: 208-211

193 Kannel WB, **Wilson PW**F, Moser M, Rich MW: What older adults should know about high cholesterol. A position paper from the Society of Geriatric Cardiology. American Journal of Geriatric Cardiology 1998; 7: 43-44

194 **Wilson PW**F: Physical activity and CHD in Preventive Cardiology (ed Robinson K) Futura, New York, 1998, pp 51-67

195 **Wilson PW**F: Diabetes mellitus, insulin resistance and CHD in Preventive Cardiology (ed Robinson K) Futura, New York, 1998, pp 69-96

196 Kannel WB, **Wilson PW**F, D'Agostino RB, Cobb J: Sudden death in women Amer Heart J 1998; 136: 205-212

197 **Wilson PW**F: Do estrogens reduce glycemic levels? (editorial) Diabetes Care 1998; 21: 1585

198 Zhang Y, McAlindon TE, Hannan MT, et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham Study. Arthritis Rheum. 1998; 41:1867-73.

199 Welty FK, Lahoz C, Tucker KL, Ordovas JM, **Wilson PW**, Schaefer EJ. Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the Framingham Offspring population. Arterioscler Thromb.Vasc.Biol. 1998; 18: 1745-1751.

200 Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, **Wilson PW**F, Wright JT Jr.: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906

201 **Wilson PW**, Culleton BF. Epidemiology of cardiovascular disease in the United States. Am J Kidney Dis. 1998; 32: S56-S65

202 **Wilson PW**. Diabetes mellitus and coronary heart disease. Am J Kidney Dis. 1998; 32: S89-100.

203 Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, **Wilson PW**F, Kiel DP. Association between insulin-like growth factor I and bone mineral density in older women and men The Framingham Heart Study. J Clin Endocrinol Metab 1998; 83: 4257-4262

204 Fleming DJ, Jacques PF, Dallal GE, Tucker KL, **Wilson PW**F, Wood RJ: Dietary determinants of iron stores in a free-living elderly population: The Framingham Heart Study. Am J Clin Nutr 1998; 67: 722-733

205 Culleton BF, **Wilson PW**F: Thrombogenic risk factors for cardiovascular disease in dialysis patients. Seminars in Dialysis 1999; 12: 117-125

206 Kannel WB, **Wilson PW**F, Larson MG, Evans JC: Coronary risk factors and coronary prevention in octogenarians in Cardiovascular Disease in the Octogenarian and Beyond (ed Wenger NK) Dunitz Press, 1999, pp 141-161

207 Haider AW, Larson MG, O'Donnell CJ, Evans JC, **Wilson PW**F, Levy D: The association of chronic cough with the risk of myocardial infarction: The Framingham Heart Study Am J Med 1999; 106: 279-284

208 Tucker KL, Chen H, Vogel S, **Wilson PW**F, Schaefer EJ, Lammi-Keefe CJ: Carotenoid intakes, assessed by dietary questionnaire, are associated with plasma carotenoid concentrations in an elderly population. J Nutrition 1999; 129: 438-445

209 Fraenkel L, Zhang Y, Chaisson CE, Maricq HR, Evans SR, Brand F, **Wilson PW**, Felson DT: Different factors influencing the expression of Raynaud's phenomenon in men and women. Arthritis Rheum. 1999; 42: 306-310

210 **Wilson PW**F, Kannel WB, Silbershatz H, D'Agostino R: Clustering of Metabolic Factors and Coronary Heart Disease. Arch Intern Med 1999; 159: 1104-1109

211 Bostom AG, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, Wolf PA, Rosenberg IH, **Wilson PW**F: Serum total homocysteine levels predict all cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077-1080

212 Jacques PF, Selhub J, Bostom AG, **Wilson PW**F, Rosenberg IH: Impact of Folic Acid Fortification on Plasma Folate and Total Homocysteine Concentrations in Middle-Aged and Older Adults from the Framingham Study. N Engl J Med 1999; 340: 1449-1454

213 Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, **Wilson PW**F, Levy D: Profile for estimating risk of heart failure. Arch Intern Med 1999; 159: 1197-1204

214 Bostom AG, Rosenberg IH, Silbershatz, Jacques PF, Selhub J, D'Agostino RB, **Wilson PW**F, Wolf PA: Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann.Intern.Med. 1999; 131: 352-355.

215 Culleton BF, Larson MG, Evans JC, **Wilson PW**F, Barrett BJ, Parfrey PS, Levy D: Prevalence and correlates of elevated serum creatinine levels: the Framingham Heart Study. Arch.Intern.Med. 1999; 159:1785-1790.

216 McAlindon TE, **Wilson PW**, Aliabadi P, Weissman B, Felson DT. Level of physical activity and the risk of radiographic and symptomatic knee osteoarthritis in the elderly: the Framingham Study. Am.J Med. 1999; 106:151-157.

217 Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara Jr, **Wilson PW**, Castelli WP, Ordovas JM, Schaefer EJ: Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin.Chem. 1999; 45: 1039-1046.

218 Tucker KL, Hannan MT, Chen H, Cupples LA, **Wilson PW**, Kiel DP. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am.J Clin.Nutr. 1999; 69: 727-736.

219 **Wilson PW**. Metabolic risk factors for coronary heart disease: current and future prospects. Curr.Opin.Cardiol. 1999; 14: 176-185.

220 Kannel WB, **Wilson PW**F: Lipid control in the pre-statin era. in Statins: The HMG CoA Reductase Inhibitors in Perspective, (eds Gaw A, Packard CJ, Shepherd J) Dunitz Press, London, 1999, pp 21-34

221 **Wilson PW**F: From hypertension to heart failure: What have we learned? Clin. Cardiol. 1999; 22(suppl V); V1-V10

222 Culleton BF, Larson MG, **Wilson PW**F, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56: 2214-2219.

223 Guidry UC, Evans JC, Larson MG, **Wilson PW**F, Murabito JM, Levy D. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation 1999;100: 2054-2059.

224 Hiller R, Podgor MJ, Sperduto RD, **Wilson PW**F, Chew EY, D'Agostino RB. High intraocular pressure and survival: the Framingham Studies. Am.J.Ophthalmol. 1999;128: 440-445

225 Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, **Wilson PW**F, Levy D. Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Arch.Intern.Med. 1999; 159: 2206-2212.

226 Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, **Wilson PW**F: Hyperinsulinemia, hyperglycemia and impaired hemostasis: The Framingham Offspring Study JAMA 2000; 283: 221-228

227 D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, **Wilson PW**, Hartz SC: Primary and subsequent coronary risk appraisal: New results from The Framingham Study. Am.Heart J. 2000; 139: 272-281

228 Tucker KL, Rich S, Rosenberg I, Jacques P, Dallal G, **Wilson PW**, Selhub J: Plasma vitamin B-12 concentrations relate to intake source in the Framingham Offspring Study(1). Am.J.Clin.Nutr. 2000; 71: 514-522

229 Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, Mittleman M, Muller JE, D'Agostino RB, **Wilson PW**, Levy D: Association of blood pressure with fibrinolytic potential in the Framingham Offspring Population. Circulation 2000; 101: 264-269
230 Couture P, Otvos JD, Cupples LA, **Wilson PW**, Schaefer EJ, Ordovas JM. Absence of association between genetic variation in the promoter of the microsomal triglyceride transfer protein gene and plasma lipoproteins in the Framingham Offspring Study. Atherosclerosis 1999; 148: 337-343.
231 Couture P, Otvos JD, Cupples LA, **Wilson PW**, Schaefer EJ, Ordovas JM. Association of the A-204C polymorphism in the cholesterol 7alpha- hydroxylase gene with variations in plasma low-density lipoprotein cholesterol levels in the Framingham Offspring Study. J.Lipid Res. 1999; 40: 1883-9
232 Couture P, Otvos JD, Cupples LA, Lahoz Cm, **Wilson PW**F, Schaefer EJ, Ordovas JM: Association of the C-514T Polymorphism in the Hepatic Lipase Gene With Variations in Lipoprotein Subclass Profiles: The Framingham Offspring Study. Arterioscler.Thromb.Vasc.Biol. 2000; 20: 815-822
233 **Wilson PW**F: Emerging risk factors for coronary artery disease. Royal Society of Medicine Monograph Series (London) 1999; 258: pp 17-25
234 Fraenkel L, Tofler GH, Zhang H, Silbershatz H, D'Agostino RB, **Wilson PW**, Felson DT: The associations between plasma levels of von Willebrand factor and fibrinogen with Raynaud's phenomenon in men and women. Am.J.Med. 2000; 108: 583-586
235 Booth SL, Tucker KL, Chen H, Hannan MT, Gagnon DR, Cupples LA, **Wilson PW**, Ordovas J, Schaefer EJ, Dawson-Hughes B, Kiel DP: Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am.J.Clin.Nutr. 2000; 71: 1201-1208.
236 Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, **Wilson PW**, Kiel DP. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study J.Bone Miner.Res. 2000; 15: 710-720.
237 Moore LL, Visioni AJ, **Wilson PW**, D'Agostino RB, Finkle WD, Ellison RC. Can sustained weight loss in overweight individuals reduce the risk of diabetes mellitus? Epidemiology 2000; 11: 269-273.
238 Shearman AM, Ordovas JM, Cupples LA, Schaefer EJ, Harmon MD, Shao Y, Keen,J.D.; DeStefano,A.L.; Joost,O.; Wilson,P.W.; Housman,D.E.; Myers,R.H.. Evidence for a gene influencing the TG/HDL-C ratio on chromosome 7q32.3- qter: a genome-wide scan in the Framingham Study. Hum.Mol.Genet. 2000; 9: 1315-1320.
239 Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, Lahoz C; Coltell O; **Wilson PW**; Schaefer EJ: Association of Cholesteryl Ester Transfer Protein-TaqIB Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk : The Framingham Study. Arterioscler Thromb.Vasc.Biol. 2000; 20: 1323-1329
240 **Wilson PW**F: The newer coronary risk factors in Atlas of Atherosclerosis: Risk Factors and Treatment (Second Edition) editor PWF Wilson, Current Science 2000 (Philadelphia, PA) 2000, pp 180-193
241 Kannel WB, **Wilson PW**F: Hypertension as a cardiovascular risk factor in Handbook of Hypertension, Volume 20: Epidemiology of Hypertension (ed C. J. Bulpitt) Elsevier Press (Amsterdam) 2000, pp 19-42
242 Meigs JB, Ordovas JM, Cupples LA, Singer DE, Nathan DM, Schaefer EJ, **Wilson PW**: Apolipoprotein E isoform polymorphisms are not associated with insulin resistance: the Framingham Offspring Study. Diabetes Care 2000; 23: 669-674
243 **Wilson PW**F, Jacques PF: Epidemiology of homocysteine levels and relation to vitamins in Homocysteine and Vascular Disease (ed K. Robinson) Kluwer Academic Publishers (Amsterdam) 2000, pp 85-95
244 **Wilson PW**F: Homocysteine: The new risk factor for cardiovascular disease in the elderly. Amer J Geriatric Cardiology 2000; 9: 185-189
245 **Wilson PW**F: Lipids, lipases, and obesity: Does race matter? Arterioscler.Thromb.Vasc.Biol (editorial) 2000; 20: 1854-1856

246 Singh JP, Larson MG, O'Donnell CJ, **Wilson P**F, Tsuji H, Lloyd-Jones DM, Levy D: Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am.J.Cardiol. 2000; 86: 309-312
247 Sonnenberg LM, Quatromoni PA, Gagnon DR, Cupples LA, Franz MM, Ordovas JM, **Wilson PW**, Schaefer EJ, Millen BP: Diet and plasma lipids in women. II. Macronutrients and plasma triglycerides, high-density lipoprotein, and the ratio of total to high- density lipoprotein cholesterol in women: the Framingham nutrition studies. J.Clin.Epidemiol. 1996; 49: 665-72
248 Millen BE, Franz MM, Quatromoni PA, Gagnon DR, Sonnenberg LM, Ordovas JM, **Wilson PW**, Schaefer EJ, Cupples LA: Diet and plasma lipids in women. I. Macronutrients and plasma total and low-density lipoprotein cholesterol in women: the Framingham nutrition studies. J.Clin.Epidemiol. 1996; 49: 657-63
249 **Wilson PW**F, Benjamin EJ, Manolio TA: Workshop on nonvalvular atrial fibrillation in the elderly: Challenges for Prevention and Care Am. J Geriatr. Cardiology 2000:5; 73S-75S
250 Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, Massaro JM, **Wilson PW**F, Muller JE, D'Agostino RB: Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring population. Circulation 2000; 102: 1634-1638
251 Meigs JB, Cupples LA, **Wilson PW**F: Parental transmission of type 2 diabetes: The Framingham Offspring Study. Diabetes 2000; 49: 2201-2207
252 Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, **Wilson PW**, Felson DT: Association of Hypogonadism and Estradiol Levels with Bone Mineral Density in Elderly Men from the Framingham Study. Ann.Intern.Med 2000; 133: 951-963
253 Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley P, **Wilson PW**, D'Agostino RB, and Grinspoon S: Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy. Clin.Infect.Dis. 2001; 32:130-139
254 McNamara JR, Shah PK, Nakajima K, Cupples LA, **Wilson PW**, Ordovas JM, Schaefer EJ: Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001; 154: 229-236
255 Gagne SE, Larson MG, Pimstone SN, Schaefer EJ, Kastelein JJ, **Wilson PW**, Ordovas JM, Hayden MR: A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. Clin.Genet. 1999; 55:450-454
256 **Wilson PW**: Lipoprotein measurements-setting priorities (editorial) Am J Med 2001; 110:71-72
257 **Wilson PW**F, Kauppila LI, O'Donnell CJ, Kiel DP, Hannan M, Polak JM, Cupples LA: Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001; 103: 1529-1534
258 Fleming DJ, Jacques PF, Tucker KL, Massaro JM, D'Agostino RB, **Wilson PW**F, Wood RJ: Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. Am J Clin Nutr 2001; 73: 638-646
259 Lloyd-Jones DM, O'Donnell CJ, Silbershatz H, D'Agostino RB, **Wilson PW**F: Applicability of cholesterol-lowering primary prevention trials to a general population. Arch Intern Med 2001; 161:949-954
260 Zee RYL, Myers RH, Hannon MT, **Wilson PW**F, Ordovas JM, Schaefer EJ, Lindpaintner K, Kiel DP: Absence of linkage for bone mineral density to chromosome 12q12-14 in the region of the vitamin D receptor gene. Calcif. Tissue Int 2000; 67: 434-439
261 Brousseau ME, Bodzioch M, Schaefer EJ, Goldkamp AL, Kielar D, Probst M, Ordovas JM, Aslanidis C, Lackner KJ, Rubins HB, Collins D, Robins SJ, **Wilson PW**F, Schmitz G: Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease Atherosclerosis 2001; 154: 607-611
262 **Wilson PW**F: Physical activity, fitness, and coronary risk estimation (editorial) J. Cardiopulmonary Rehabilitation 2001; 21:71-72

263 de Kleijn MJJ, van der Schouw YT, **Wilson PW**, Adlercreutz H, Mazur W, Grobbee DE, Jacques PF. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham Study. J Nutr 2001; 131;1826-1832
264 Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, **Wilson PW**F. Bone loss and progression of abdominal aortic calcification over a 25-year period: The Framingham Heart Study. Calcif.Tissue Int 2001; 68; 271-276
265 Hadigan C, Meigs JB, Rabe J, D'Agostino RB, **Wilson PW**, Lipinska I, Tofler GH, Grinspoon SS. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86: 939-943
266 Jacques PF, Bostom AG, **Wilson PW**, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001; 73: 613-621
267 Lahoz C, Schaefer EJ, Cupples LA, **Wilson PW**, Levy D, Osgood D, Parpos S, Pedro-Botet S, Daly JA, Ordovas JM. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001; 154: 529-537
268 Corella D, Tucker K, Lahoz C, Coltell O, Cupples LA, **Wilson PW**, Schaefer EJ, Ordovas JM. Alcohol drinking determines the effect of the APOE locus on LDL- cholesterol concentrations in men: the Framingham Offspring Study. Am J Clin Nutr 2001; 73:736-745
269 Friso S, Jacques PF, **Wilson PW**, Rosenberg IH, Selhub J. Low circulating vitamin B_6 is associated with elevation of the inflammation marker c-reactive protein independently of plasma homocysteine levels. Circulation 2001; 103:2788-2791
270 Galluzzi JR, Cupples LA, Meigs JB, **Wilson PW**, Schaefer EJ, Ordovas JM: Association of the Ala54-thr Polymorphism in the Intestinal Fatty Acid-Binding Protein With 2-h Postchallenge Insulin Levels in the Framingham Offspring Study. Diabetes Care 2001; 24:1161-1166
271 D'Agostino, RB Sr., Grundy S, Sullivan LM, **Wilson P**: Validation of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic Groups Investigation. JAMA 2001; 286:180-187
272 Grundy SM, D'Agostino RB Sr, Mosca L, Burke GL, **Wilson PW**, Rader DJ, Cleeman JI, Roccella EJ, Cutler EA, Friedman LM: Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation 2001; 104: 491-496
273 Russo GT, Meigs JB, Cupples LA, Demissie S, Otvos JD, **Wilson PW**, Lahoz C, Cucinotta D, Couture P, Mallory T, Schaefer EJ, Ordovas JM: Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham Offspring Study. Atherosclerosis 2001;158:173-81.
274 Worzala K, Hiller R, Sperduto RD, Mutalik K, Murabito JM, Moskowitz M, D'Agostino RB, **Wilson PW**: Postmenopausal estrogen use, type of menopause, and lens opacities: the Framingham studies. Arch.Intern.Med 2001;161:1448-54.
275 Meigs JB, Haffner SM, Nathan DM, D'Agostino RB, **Wilson PW**: Sample exchange to compare insulin measurements between the San Antonio Heart Study and the Framingham Offspring Study. J Clin Epidemiol. 2001; 54:1031-1036
276 Mukamal KJ, Jadhav PP, D'Agostino RB, Massaro JM, Mittleman MA, Lipinska I, Sutherland PA, Matheney T, Levy D, **Wilson PW**, Ellison RC, Silbershatz H, Muller JE, Tofler GH: Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. Circulation 2001; 104:1367-1373
277 Haveman-Nies A,Tucker KL, de Groot LC, Wilson, van Staveren WA: Evaluation of dietary quality in relationship to nutritional and lifestyle factors in elderly people of the US Framingham Heart Study and the European SENECA Study. Eur.J Clin Nutr 2001; 55: 870-880, 2001.
278 Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, **Wilson PW**: Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study. Stroke 2001; 32: 2575-2579, 2001.
279 Thompson G, Dean J, **Wilson PW**F: Dyslipidaemia in Clinical Practice. Martin Dunitz, London 2002

280 Seshadri S, Wolf PA, Beiser A, Vasan RS, **Wilson PW**, Kase CS. Kelly-Hayes M, Kannel WB and D'Agostino RB: Elevated midlife blood pressure increases stroke risk in elderly persons: the Framingham Study. Arch.Intern Med 2001; 161: 2343-2350
281 Murabito JM, Evans JC, Larson MG, Kreger BE, Splansky GL, Freund KM, Moskowitz MA, **Wilson PW**: Family breast cancer history and mammography: Framingham Offspring Study. Am J Epidemiol. 2001; 154: 916-923
282 **Wilson PW**F: Diabetes Mellitus and Coronary Heart Disease. Endocrinology and Metabolism Clinics of North America 2001; 30: 857-882
283 Vasan RS, Massaro JM, **Wilson PW**, Seshadri S, Wolf PA, Levy D, D'Agostino RB: Antecedent blood pressure and risk of cardiovascular disease: the Framingham Heart Study. Circulation 2002; 105:48-53
284 Ordovas JM, Corella D, Cupples LA, Demissie S, Kelleher A, Coltell O, **Wilson PW**, Schaefer EJ, Tucker K: Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study. Am J Clin Nutr 2002; 75:38-46
285 Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, **Wilson PW**, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N.Engl.J Med 2002; 346: 476-483
286 Jacques PF, Kalmbach R, Bagley PJ, Russo GT, Rogers G, **Wilson PW**, Rosenberg IH, Selhub J: The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr 2002; 132: 283-288
287 de Kleijn MJ, van der Schouw YT, **Wilson PW**, Grobbee DE, Jacques PF: Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S.women: the Framingham Study. J Nutr 2002; 132:276-282
288 Meigs JB, Panhuysen CI, Myers RH, **Wilson PW**, Cupples LA. A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study. Diabetes 2002; 51:833-840.
289 **Wilson PW**, Kannel WB. Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol 2002; 11:119-123
290 Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, D'Agostino RB, Sr., and **Wilson PW**. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes Care 2001; 24:1403-1410
291 de Kleijn MJ, van der Schouw YT, **Wilson PW**, Grobbee DE, Jacques PF. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S.women: The Framingham Study. J Nutr 2002; 132: 276-282
292 Jacques PF, Kalmbach R, Bagley PJ, Russo GT, Rogers G, **Wilson PW** et al. The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr 2002; 132: 283-288
293 Meigs JB, D'Agostino RB, Sr., Nathan DM, Rifai N, **Wilson PW**. Longitudinal Association of Glycemia and Microalbuminuria: The Framingham Offspring Study. Diabetes Care 2002; 25: 977-983
294 Meigs JB, Panhuysen CI, Myers RH, **Wilson PW**, Cupples LA. A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study. Diabetes 2002; 51:833-840
295 McKeown NM, Jacques PF, Gundberg CM, Peterson JW, Tucker KL, Kiel DP, **Wilson PW**, Booth SL. Dietary and nondietary determinants of vitamin K biochemical measures in men and women. J Nutr 2002; 132:1329-1334
296 Redberg RF, Greenland P, Fuster V, Pyorala K, Blair SN, Folsom AR, Newman AB, O'Leary DH, Orchard TJ, Psaty B, Schwartz JS, Starke R, **Wilson PW**. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group III: risk assessment in persons with diabetes. Circulation 2002; 105:e144-e152

297 Tai ES, Demissie S, Cupples LA, Corella D, **Wilson PW**, Schaefer EJ, Ordovas JM. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002; 22:805-810
298 Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM, **Wilson PW**. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002; 25:989-994
299 Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, **Wilson PW**: Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am.Heart J. 2002; 143:961-965
300 Tucker KL, Chen H, Hannan MT, Cupples LA, **Wilson PW**, Felson D, Kiel DP: Bone mineral density and dietary patterns in older adults: the Framingham Osteoporosis Study. Am.J.Clin.Nutr. 2002; 76:245-252
301 Vargas-Martinez C, Ordovas JM, **Wilson PW**, Selhub J: The glutamate carboxypeptidase gene II (C>T) polymorphism does not affect folate status in the Framingham Offspring cohort. J.Nutr. 2002; 132:1176-1179
302 Meigs JB, Larson MG, D'Agostino RB, Levy D, Clouse ME, Nathan DM, **Wilson PW**, O'Donnell CJ. Coronary Artery Calcification in Type 2 Diabetes and Insulin Resistance: The Framingham Offspring Study. Diabetes Care 2002; 25:1313-1319.
303 McKeown NM, Meigs JB, Liu S, **Wilson PW**, Jacques PF. Whole-grain intake is favorably associated with metabolic risk factors for type 2 diabetes and cardiovascular disease in the Framingham Offspring Study. Am J Clin Nutr 2002; 76:390-398
304 Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, **Wilson PW**, Sutherland P, Omland T, Vasan RS. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90:254-258
305 O'Donnell CJ, Chazaro I, **Wilson PW**, Fox C, Hannan MT, Kiel DP, Cupples LA. Evidence for heritability of abdominal aortic calcific deposits in the Framingham Heart Study. Circulation 2002; 106:337-341
306 Kenchaiah S, Evans JC, Levy D, **Wilson PW**, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N.Engl.J.Med. 2002; 347:305-313
307 Wang TJ, Larson MG, Levy D, Benjamin EJ, Kupka MJ, Manning WJ, Clouse ME, D'Agostino RB, **Wilson PW**, O'Donnell CJ. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation 2002; 106:1189-1191
308 **Wilson P**.W.F. Homocysteine, vitamins and coronary artery disease. In: Braunwald E, editor. *Harrison's Advances in Cardiology*. New York: McGraw-Hill, 2002: 18-23
309 **Wilson PW**, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162:1867-1872
310 Choumenkovitch SF, Selhub J, **Wilson PW**, Rader JI, Rosenberg IH, Jacques PF. Folic Acid Intake from Fortification in United States Exceeds Predictions. J Nutr 2002; 132:2792-2798
311 Karasik D, Rosen CJ, Hannan MT, Broe KE, Dawson-Hughes B, Gagnon DR, **Wilson PW**, Visser M, Langlois JA, Mohan S, Kiel DP. Insulin-Like Growth Factor Binding Proteins 4 and 5 and Bone Mineral Density in Elderly Men and Women. Calcif Tissue Int 2002; 71: 323-328
312 Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, **Wilson PW**, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA 2002; 288:1252-1259.
313 Meigs JB, Nathan DM, D'Agostino RB, Sr., **Wilson PW**: Fasting and Postchallenge Glycemia and Cardiovascular Disease Risk: The Framingham Offspring Study. Diabetes Care 2002; 25:1845-1850
314 Ordovas JM, Corella D, Demissie S, Cupples LA, Couture P, Coltell O, **Wilson PW**, Schaefer EJ, Tucker KL. Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study. Circulation 2002; 106:2315-2321

315 Haider AW, **Wilson PW**, Larson MG, Evans JC, Michelson EL, Wolf PA, O'Donnell CJ, Levy D. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease. A prospective study. J Am Coll Cardiol 2002; 40:1408-1413
316 **Wilson PW**. Homocysteine and coronary heart disease: how great is the hazard? JAMA 2002; 288:2042-2043
317 **Wilson PW**. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. Curr Cardiol Rep 2002; 4:486
318 **Wilson PW**. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Curr Cardiol Rep 2002; 4:486-487
319 **Wilson PW**. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL Study: a randomized controlled trial. Curr Cardiol Rep 2002; 4:485
320 Wang TJ, Nam BH, **Wilson PW**, Wolf PA, Levy D, Polak JF, D'Agostino RB, O'Donnell CJ. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002; 22:1662-1667
321 Walsh CR, Cupples LA, Levy D, Kiel DP, Hannan M, **Wilson PW**, O'Donnell CJ. Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: the Framingham Heart Study. Am Heart J 2002; 144:733-739
322 Kannel WB, **Wilson PW**, Nam BH, D'Agostino RB. Risk stratification of obesity as a coronary risk factor. Am J Cardiol 2002; 90:697-701
323 Fleming DJ, Tucker KL, Jacques PF, Dallal GE, **Wilson PW**, Wood RJ. Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. Am J Clin Nutr 2002; 76:1375-1384
324 Tofler GH, D'Agostino RB, Jacques PF, Bostom AG, **Wilson PW**, Lipinska I, Mittleman MA, Selhub J. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. Thromb Haemost 2002; 88:799-804
325 Atwood LD, Heard-Costa NL, Cupples LA, Jaquish CE, **Wilson PW**, D'Agostino RB. Genomewide Linkage Analysis of Body Mass Index across 28 Years of the Framingham Heart Study. Am J Hum Genet 2002; 71:1044-1050
326 Booth SL, Broe KE, Gagnon DR, Tucker KL, Hannan MT, McLean RR, Dawson-Hughes B, **Wilson PW**, Cupples LA, Kiel DP. Vitamin K intake and bone mineral density in women and men. Am J Clin Nutr 2003; 77:512-516
327 **Wilson PW**. Lower diabetes risk with hormone replacement therapy: an encore for estrogen? Ann Intern Med 2003; 138:69-70
328 Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, Nesto RW, **Wilson PW**, Vasan RS. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003; 107:448-454
329 Freitag MH, Larson MG, Levy D, Benjamin EJ, Wang TJ, Leip EP, **Wilson PW**, Vasan RS. Plasma Brain Natriuretic Peptide Levels and Blood Pressure Tracking in the Framingham Heart Study. Hypertension 2003; 41: 978-983
330 Hiller R, Sperduto RD, Reed GF, D'Agostino RB, **Wilson PW**. Serum lipids and age-related lens opacities: a longitudinal investigation: the Framingham Studies. Ophthalmology 2003; 110:578-583
331 Keaney JF, Jr., Larson MG, Vasan RS, **Wilson PW**, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23:434-439
332 Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, Rosenberg IH, **Wilson PW**. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003; 289:1251-1257
333 McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, **Wilson PW**, D'Agostino RB, O'Donnell CJ, Patel DD, Murphy PM. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive

function and correlates with protection from cardiovascular disease in humans. J Clin Invest 2003; 111:1241-1250
334 Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, **Wilson PW**, D'Agostino RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107:1486-1491
335 Hadigan C, Meigs JB, **Wilson PW**, D'Agostino RB, Davis B, Basgoz N, Sax PE, Grinspoon S. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003; 36:909-916
336 Keaney JF, Jr., Larson MG, Vasan RS, **Wilson PW**, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23:434-439
337 Osgood D, Corella D, Demissie S, Cupples LA, **Wilson PW**, Meigs JB, Schaefer EJ, Coltell O, Ordovas JM. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the Framingham Study. J Clin Endocrinol Metab 2003; 88:2869-2879
338 Tan ZS, Seshadri S, Beiser A, **Wilson PW**, Kiel DP, Tocco M, D'Agostino RB, Wolf PA. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 2003; 163:1053-1057
339 Panhuysen CI, Cupples LA, **Wilson PW**, Herbert AG, Myers RH, Meigs JB. A genome scan for loci linked to quantitative insulin traits in persons without diabetes: the Framingham Offspring Study. Diabetologia 2003; 46:579-587
340 Wang TJ, Nam BH, D'Agostino RB, Wolf PA, Lloyd-Jones DM, MacRae CA, **Wilson PW**, Polak JF, O'Donnell CJ. Carotid Intima-Media Thickness Is Associated With Premature Parental Coronary Heart Disease. The Framingham Heart Study. Circulation 2003; 108: 572-576
341 **Wilson PW**, Smith SC, Jr., Blumenthal RS, Burke GL, Wong ND. 34th Bethesda Conference: Task force #4--How do we select patients for atherosclerosis imaging? J Am Coll Cardiol 2003; 41:1898-1906
342 Pasternak RC, Abrams J, Greenland P, Smaha LA, **Wilson PW**, Houston-Miller N. 34th Bethesda Conference: Task force #1--Identification of coronary heart disease risk: is there a detection gap? J Am Coll Cardiol 2003; 41:1863-1874
343 Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, **Wilson PW**. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9:237-252
344 Payette H, Roubenoff R, Jacques PF, Dinarello CA, **Wilson PW**, Abad LW, Harris T. Insulin-Like Growth Factor-1 and Interleukin 6 Predict Sarcopenia in Very Old Community-Living Men and Women: The Framingham Heart Study. J Am Geriatr Soc 2003; 51:1237-1243
345 **Wilson PW**, Smith SC, Jr., Blumenthal RS, Burke GL, Wong ND. 34th Bethesda Conference: Task force #4--How do we select patients for atherosclerosis imaging? J Am Coll Cardiol 2003; 41: 1898-1906
346 Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, **Wilson PW**. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290: 891-897
347 Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, **Wilson PW**. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med 2003; 163:1939-1942
348 Lloyd-Jones DM, **Wilson PW**, Larson MG, Leip E, Beiser A, D'Agostino RB et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med 2003; 163:1966-1972
349 **Wilson PW**, Grundy SM. The metabolic syndrome: practical guide to origins and treatment: Part I Circulation 2003; 108:1422-1424, Part II Circulation 2003; 108:1537-1540

350 **Wilson PW**. The antihypertensive and lipid-lowering treatment to prevent heart attack trial: modest effects on lipids and heart disease. Curr Cardiol Rep 2003; 5:461
351 **Wilson PW**. The anglo-scandinavian cardiac outcomes trial lipid-lowering arm: significant lipid and coronary heart disease effects. Curr Cardiol Rep 2003; 5:462
352 Roubenoff R, Parise H, Payette HA, Abad LW, D'Agostino R, Jacques PF et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med 2003; 115:429-435
353 Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med 2003; 139:642-648
354 Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, **Wilson PW**. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154-2169. also in Hypertension 2003; 42:1050-1065
355 Russo GT, Friso S, Jacques PF, Rogers G, Cucinotta D, **Wilson PW**, Ordovas JM, Rosenberg IH, Selhub J. Age and Gender Affect the Relation between Methylenetetrahydrofolate Reductase C677T Genotype and Fasting Plasma Homocysteine Concentrations in the Framingham Offspring Study Cohort. J Nutr 2003; 133: 3416-3421
356 Lin JP, Cupples LA, **Wilson PW**, Heard-Costa N, O'Donnell CJ. Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham Study. Am J Hum Genet 2003; 72:1029-1034
357 Janardhan V, Wolf PA, Kase CS, Massaro JM, D'Agostino RB, Franzblau C, **Wilson PW**. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and Offspring Study. Stroke 2004; 35:736-741
358 McKeown NM, Meigs JB, Liu S, Saltzman E, **Wilson PW**, Jacques PF: Carbohydrate Nutrition, Insulin Resistance, and the Prevalence of the Metabolic Syndrome in the Framingham Offspring Cohort. Diabetes Care 2004; 27:538-546
359 Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, **Wilson PW**, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109:594-600
360 Fox CS, Larson MG, Leip EP, Culleton B, **Wilson PW**, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291:844-850
361 Samelson EJ, Cupples LA, Hannan MT, **Wilson PW**, Williams SA, Vaccarino V, Zhang Y, Kiel DP. Long-term effects of serum cholesterol on bone mineral density in women and men: the Framingham Osteoporosis Study. Bone 2004; 34:557-561
362 Samelson EJ, Kiel DP, Broe KE, Zhang Y, Cupples LA, Hannan MT, **Wilson PW**, Levy D, Williams SA, Vaccarino V. Metacarpal cortical area and risk of coronary heart disease: the Framingham Study. Am J Epidemiol 2004; 159:589-595
363 Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, **Wilson PW**. Relations of Serum Aldosterone to Cardiac Structure. Gender-Related Differences in the Framingham Heart Study. Hypertension 2004; 43: 957-962
364 Fox CS, Heard-Costa NL, **Wilson PW**, Levy D, D'Agostino RB, Sr., Atwood LD. Genome-Wide Linkage to Chromosome 6 for Waist Circumference in the Framingham Heart Study. Diabetes 2004; 53:1399-1402
365 Fox CS, Sullivan L, D'Agostino RB, Sr., **Wilson PW**. The Significant Effect of Diabetes Duration on Coronary Heart Disease Mortality: The Framingham Heart Study. Diabetes Care 2004; 27:704-708
366 Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples LA, Parise H, D'Agostino RB, **Wilson PW**, Schaefer EJ. Sex and Age Differences in Lipoprotein Subclasses Measured by Nuclear Magnetic Resonance Spectroscopy: The Framingham Study. Clin Chem 2004; 50: 1189-1200

367 Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R, Jr., Levin A, Masri B, Parekh R, Wanner C, Wheeler DC, **Wilson PW**. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4 Suppl 7:13-53
368 Murabito JM, Nam BH, D'Agostino RB, Sr., Lloyd-Jones DM, O'Donnell CJ, **Wilson PW**. Accuracy of offspring reports of parental cardiovascular disease history: the Framingham Offspring Study. Ann Intern Med 2004; 140:434-440
369 Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, **Wilson PW**, Levy D, Muller JE, Tofler GH. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004; 91:683-689
370 Sundstrom J, Sullivan L, Selhub J, Benjamin EJ, D'Agostino RB, Jacques PF, Rosenberg IH, Levy D, **Wilson PW**, Vasan RS. Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. Eur Heart J 2004; 25:523-530
371 Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, **Wilson PW**. Relations of Serum Aldosterone to Cardiac Structure. Gender-Related Differences in the Framingham Heart Study. Hypertension 2004; 43: 957-962
372 Haider AW, Roubenoff R, **Wilson PW**, Levy D, D'Agostino R, Silbershatz H, O'Donnell CJ. Monocyte cytokine production, systemic inflammation and cardiovascular disease in very elderly men and women: The Framingham Heart Study. Eur J Cardiovasc Prev Rehabil 2004; 11:214-215
373 Liu J, Hong Y, D'Agostino RB, Sr., Wu Z, Wang W, Sun J, **Wilson PW**, Kannel WB, Zhao D. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004; 291:2591-2599
374 Meigs JB, Williams K, Sullivan LM, Hunt KJ, Haffner SM, Stern MP, Gonzalez VC, Perhanidis JS, Nathan DM, D'Agostino RB, Jr., D'Agostino RB, Sr., **Wilson PW**. Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care 2004; 27:1417-1426
375 Lloyd-Jones DM, Nam BH, D'Agostino RB, Sr., Levy D, Murabito JM, Wang TJ, **Wilson PW**, O'Donnell CJ. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004; 291:2204-2211
376 **Wilson PW**F: Assessing coronary heart disease risk with traditional and novel risk factors. Clin Cardiol 2004; 27 (Suppl III); 7-11
377 Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Sutherland P, **Wilson PW**, Vasan RS. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004; 109:2850-2856
378 Smith SC, Jr., Milani RV, Arnett DK, Crouse JR, III, McDermott MM, Ridker PM, Rosenson RS, Taubert KA, **Wilson PW**. Atherosclerotic vascular disease conference: Writing Group II: risk factors. Circulation 2004; 109:2613-2616
379 Ridker PM, **Wilson PW**, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109:2818-2825
380 Kannel WB, D'Agostino RB, Sullivan L, **Wilson PW**. Concept and usefulness of cardiovascular risk profiles. Am Heart J 2004; 148:16-26
381 Lloyd-Jones DM, **Wilson PW**, Larson MG, Beiser A, Leip EP, D'Agostino RB, Levy D. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004; 94:20-24
382 Vasan RS, Evans JC, Larson MG, **Wilson PW**, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351:33-41

383 Keaney JF, Jr., Massaro JM, Larson MG, Vasan RS, **Wilson PW**, Lipinska I, Corey D, Sutherland P, Vita JA, Benjamin EJ. Heritability and correlates of intercellular adhesion molecule-1 in the Framingham Offspring Study. J Am Coll Cardiol 2004; 44:168-173
384 Kannel WB, **Wilson PW**, Nam BH, D'Agostino RB, Li J. A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol 2004; 94:380-384
385 Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., **Wilson PW**. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110:380-385
386 **Wilson PW**. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin North Am 2004; 33:467-481
387 **Wilson PW**. Framingham and European risk algorithms: implications for African Americans. Rev Cardiovasc Med 2004; 5 Suppl 3:S34-S41
388 **Wilson PW**. Coronary atherosclerosis progression by intravascular ultrasound with intensive versus moderate lipid lowering. Curr Cardiol Rep 2004; 6:437-438
389 **Wilson PW**. Recombinant apolipoprotein a-I milano effects on coronary atherosclerosis. Curr Cardiol Rep 2004; 6:438
390 Booth SL, Broe KE, Peterson JW, Cheng DM, Dawson-Hughes B, Gundberg CM, Cupples LA, **Wilson PW**, Kiel DP. Associations between Vitamin K Biochemical Measures and Bone Mineral Density in Men and Women. J Clin Endocrinol Metab 2004; 89:4904-4909
391 Meigs JB, Dupuis J, Herbert AG, Liu C, **Wilson PW**, Cupples LA. The Insulin Gene Variable Number Tandem Repeat and Risk of Type 2 Diabetes in a Population-Based Sample of Families and Unrelated Men and Women. J Clin Endocrinol Metab 2004; 90: 1137-1143
392 Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, **Wilson PW**, Vasan RS. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham Heart Study. Eur Heart J 2004; 25:1509-1516
393 Fox CS, Yang Q, Cupples LA, Guo CY, Larson MG, Leip EP, **Wilson PW**, Levy D. Genomewide linkage analysis to serum creatinine, GFR, and creatinine clearance in a community-based population: the Framingham Heart Study. J Am Soc Nephrol 2004; 15:2457-2461
394 Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RB, Sr., **Wilson PW**, Savage PJ. Trends in cardiovascular complications of diabetes. JAMA 2004; 292:2495-2499
395 Vita JA, Keaney JF, Jr., Larson MG, Keyes MJ, Massaro JM, Lipinska I, Lehman BT, Fan S, Osypiuk E, **Wilson PW**, Vasan RS, Mitchell GF, Benjamin EJ. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation 2004; 110:3604-3609
396 **Wilson PW**F: The epidemiology of atherosclerotic disease. Chapter 2 in Molecular mechanisms of atherosclerosis, ed. J Loscalzo, 2005 Taylor & Francis (London), pp 3-28
397 Vita JA, Keaney JF, Jr., Larson MG, Keyes MJ, Massaro JM, Lipinska I, Lehman BT, Fan S, Osypiuk E, **Wilson PW**, Vasan RS, Mitchell GF, Benjamin EJ. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation 2004; 110:3604-3609
398 **Wilson PW**. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. Circulation 2004; 110:e568-e571
399 Braam L, McKeown N, Jacques P, Lichtenstein A, Vermeer C, **Wilson P**, Booth S. Dietary phylloquinone intake as a potential marker for a heart-healthy dietary pattern in the Framingham Offspring cohort. J Am Diet Assoc 2004; 104:1410-1414
400 Fortmann SP, Ford E, Criqui MH, Folsom AR, Harris TB, Hong Y, Pearson TA, Siscovick D, Vinicor F, **Wilson P**F. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the population science discussion group. Circulation 2004; 110:e554-e559

401 Fox CS, Yang Q, Guo CY, Cupples LA, **Wilson PW**, Levy D et al. Genome-wide linkage analysis to urinary microalbuminuria in a community-based sample: The Framingham Heart Study. Kidney Int. 2005;67:70-4
402 Cendoroglo MS, Lahoz C, Martinez TL, Ordovas JM, Lamon-Fava S, Cupples LA, **Wilson PW**, Schaefer EJ. Association of apo A-IV 360 (Gln --> His) polymorphism with plasma lipids and lipoproteins: the Framingham Offspring Study. Atherosclerosis 2005; 179:169-175
403 Nanchahal K, Morris JN, Sullivan LM, **Wilson PW**. Coronary heart disease risk in men and the epidemic of overweight and obesity. Int J Obes Relat Metab Disord 2005; 29:317-323
404 Meigs JB, Dupuis J, Herbert AG, Liu C, **Wilson PW**, Cupples LA. The insulin gene variable number tandem repeat and risk of type 2 diabetes in a population-based sample of families and unrelated men and women. J Clin Endocrinol Metab 2005; 90:1137-1143
405 Yang Q, Lai CQ, Parnell L, Cupples LA, Adiconis X, Zhu Y, **Wilson PW**, Housman DE, Shearman AM, D'Agostino RB, Ordovas JM. Genome-wide linkage analyses and candidate gene fine mapping for HDL3 cholesterol: the Framingham Study. J Lipid Res 2005; 46: 1416-1425
406 Vasan RS, Sullivan LM, **Wilson PW**, Sempos CT, Sundstrom J, Kannel WB, Levy D, D'Agostino RB. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005; 142: 393-402
407 Murabito JM, Yang Q, Fox C, **Wilson PW**, Cupples LA. Heritability of Age at Natural Menopause in the Framingham Heart Study. J Clin Endocrinol Metab 2005; 90: 3427-3430
408 Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS, **Wilson PW**, Rifai N, Meigs JB, Ricken G, Lifton RP, Levy D, Vasan RS. Clinical and Genetic Correlates of Serum Aldosterone in the Community: The Framingham Heart Study. Am J Hypertens 2005; 18:657-665
409 Herbert A, Liu C, Karamohamed S, Schiller J, Liu J, Yang Q, **Wilson PW**, Cupples LA, Meigs JB. The -174 IL-6 GG genotype is associated with a reduced risk of type 2 diabetes mellitus in a family sample from the National Heart, Lung and Blood Institute's Framingham Heart Study. Diabetologia 2005; 48:1492-1495
410 Erkkila AT, Lichtenstein AH, Jacques PF, Hu FB, **Wilson PW**, Booth SL. Determinants of plasma dihydrophylloquinone in men and women. Br J Nutr 2005; 93:701-708
411 Djousse L, Levy D, Herbert AG, **Wilson PW**, D'Agostino RB, Cupples LA, Karamohamed S, Ellison RC. Influence of Alcohol Dehydrogenase 1C Polymorphism on the Alcohol-Cardiovascular Disease Association (from the Framingham Offspring Study). Am J Cardiol 2005; 96:227-232
412 Rother J, Steg PG, Ohman EM, Bhatt DL, **Wilson PW**. Atherothrombosis and Stroke - A Lot More to Know! Cerebrovasc Dis 2005; 20:139-140
413 **Wilson PW**F. The newer coronary risk factors in Atlas of Atherosclerosis, Fourth Edition (ed Grundy S) Current Medicine 2005, pp 169-185
414 Meigs JB, **Wilson PW**F, Goldberg IJ, Semenkovich CF, Ginsberg HN. Diabetes mellitus and vascular disease risk in Atlas of Atherosclerosis, Fourth Edition (ed Grundy S) Current Medicine 2005, pp 214-233
415 **Wilson PW**F. Atherosclerosis: Risk factors and treatment in Essential Atlas of Heart Diseases, Third Edition. (ed Braunwald, E), Current Medicine 2005, pp 1-24
416 Murabito JM, Evans JC, D'Agostino RB, Sr., **Wilson PW**, Kannel WB. Temporal Trends in the Incidence of Intermittent Claudication from 1950 to 1999. Am J Epidemiol 2005; 162: 1-8
417 Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Thompson SG, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D'Agostino R, Kannel WB, **Wilson PW**, Tofler G, Arocha-Pinango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Coll E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssonen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper

JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Iso H, Salomaa V, Harald K, Rasi V, Vahtera E, Jousilahti P, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben Shlomo Y, Davey SG, Palmieri V, Yeh JL, Meade TW, Rudnicka A, Knottenbelt C, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799-1809

418 **Wilson PW**. Cardiac rehabilitation and getting to lipid goals. J Cardiopulm Rehabil 2005; 25:264-265

419 **Wilson PW**. Estimating the risk for atherothrombosis: are current approaches sufficient? Eur J Cardiovasc Prev Rehabil 2005; 12:427-432

420 Murabito JM, Yang Q, Fox C, **Wilson PW**, Cupples LA. Heritability of Age at Natural Menopause in the Framingham Heart Study. Obstet Gynecol Surv 2005; 60:656-657

421 Fox CS, Larson MG, Leip EP, Meigs JB, **Wilson PW**, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 2005; 28:2436-2440

422 Dupuis J, Larson MG, Vasan RS, Massaro JM, **Wilson PW**, Lipinska I, Corey D, Vita JA, Keaney JF, Jr., Benjamin EJ. Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: Evidence for susceptibility loci on 1q. Atherosclerosis 2005; 182:307-314

423 **Wilson PW**. Treatment to New Targets Trial Results: Lower LDL-C is better for the heart. Curr Cardiol Rep 2005; 7:443-444

424 **Wilson PW**. Testing Whether Lower Low-density Lipoprotein Cholesterol or C-reactive Protein Really Determines Lower Risk for Heart Disease. Curr Cardiol Rep 2005; 7:443

425 Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., **Wilson PW**. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54:3252-3257

426 **Wilson PW**, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112:3066-3072

427 **Wilson PW**, Nam BH, Pencina M, D'Agostino RB, Sr., Benjamin EJ, O'Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005; 165:2473-2478

428 Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, **Wilson PW**, D'Agostino RB, Vasan RS, Robins SJ. Increased Small Low-Density Lipoprotein Particle Number. A Prominent Feature of the Metabolic Syndrome in the Framingham Heart Study. Circulation 2006; 113: 20-29

429 Murabito JM, Pencina MJ, Nam BH, D'Agostino RB, Sr., Wang TJ, Lloyd-Jones D, **Wilson PW**, O'Donnell CJ. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA 2005; 294:3117-3123

430 **Wilson PW**F: Cardiovascular disease risk factors in women in Women and Heart Disease (eds Wenger NK, Collins P), Taylor and Francis 2005 (Abingdon, UK) p 17-31

431 Karasik D, Kiel DP, Kiely DK, Cupples LA, **Wilson PW**, O'donnell CJ, Felson DT. Abdominal Aortic Calcification and Exostoses at the Hand and Lumbar Spine: The Framingham Study. Calcif Tissue Int 2006; 78:1-8

432 Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, **Wilson PW**. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295:180-189

433 Najarian RM, Sullivan LM, Kannel WB, **Wilson PW**, D'Agostino RB, Wolf PA. Metabolic Syndrome Compared With Type 2 Diabetes Mellitus as a Risk Factor for Stroke: The Framingham Offspring Study. Arch Intern Med 2006; 166:106-111

434 Meigs JB, O'Donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D'Agostino RB, **Wilson PW**. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 2006; 55:530-537
435 Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, **Wilson PW**, D'Agostino RB, Vasan RS, Robins SJ. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113:20-29
436 **Wilson PW**F: Coronary heart disease risk: Origins, factors and utility. In Atlas of Cardiovascular Risk Factors (ed Gaziano JM) Current Medicine 2006, pp 37-48
437 Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, **Wilson PW**, Wolf PA, Levy D. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. Circulation 2006; 113(6):791-798
438 Thompson G, Morrell J, **Wilson P**: Dyslipidaemia in Clinical Practice (Second Edition) (Informa Healthcare 2006
439 **Wilson PW**, Ben Yehuda O, McNamara J, Massaro J, Witztum J, Reaven PD. Autoantibodies to oxidized LDL and cardiovascular risk: The Framingham Offspring Study. Atherosclerosis 2006; 189: 364-368
440 Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Mas JL, Richard AJ, Rother J, **Wilson PW**. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006; 151:e1-10.
441 Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, Keaney JF, Jr., **Wilson PW**, Newton-Cheh C, Musone SL, Camargo AL, Drake JA, Levy D, O'Donnell CJ, Hirschhorn JN, Benjamin EJ. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113:1415-1423
442 Patel MR, Donahue M, **Wilson PW**, Califf RM. Clinical trial issues in weight-loss therapy. Am Heart J 2006; 151:633-642
443 Amin S, Zhang Y, Felson DT, Sawin CT, Hannan MT, **Wilson PW**, Kiel DP. Estradiol, Testosterone, and the Risk for Hip Fractures in Elderly Men from the Framingham Study. Am J Med 2006; 119:426-433
444 **Wilson PW**. Adiposity in youth and blood pressure. Hypertension 2006; 48:21-22
445 Patel MR, Donahue M, **Wilson PW**, Califf RM. Clinical trial issues in weight-loss therapy. Am Heart J 2006; 151:633-642
446 Meigs JB, Dupuis J, Liu C, O'Donnell CJ, Fox CS, Kathiresan S, Gabriel SB, Larson MG, Yang Q, Herbert AG, **Wilson PW**, Feng D, Tofler GH, Cupples LA. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample. Obesity (Silver Spring) 2006; 14:753-758
447 Meigs JB, **Wilson PW**, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D'Agostino RB. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91:2906-2912
448 Lievers KJ, Kluijtmans LA, Blom HJ, **Wilson PW**, Selhub J, Ordovas JM. Association of a 31 bp VNTR in the CBS gene with postload homocysteine concentrations in the Framingham Offspring Study. Eur J Hum Genet 2006; 14(10):1125-1129
449 Kok HS, van Asselt KM, van der Schouw YT, van dT, I, Peeters PH, **Wilson PW**, Pearson PL, Grobbee DE. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol 2006; 47:1976-1983
450 Brosius FC, III, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, Pennathur S, Smith GL, **Wilson PW**. Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease. A Science Advisory From the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working

Group Developed in Collaboration With the National Kidney Foundation. Circulation 2006; 114:1083-1087

451 Smith SR, **Wilson PW**. Free fatty acids and atherosclerosis--guilty or innocent? J Clin Endocrinol Metab 2006; 91: 2506-2508

452 O'Donnell CJ, Shea MK, Price PA, Gagnon DR, **Wilson PW**, Larson MG, Kiel DP, Hoffmann U, Ferencik M, Clouse ME, Williamson LM, Cupples LA, Dawson-Hughes B, Booth SL. Matrix Gla Protein Is Associated With Risk Factors for Atherosclerosis but not With Coronary Artery Calcification. Arterioscler Thromb Vasc Biol 2006; 26(12): 2769-2774

453 Rumawas ME, McKeown NM, Rogers G, Meigs JB, **Wilson PW**, Jacques PF. Magnesium intake is related to improved insulin homeostasis in the Framingham Offspring cohort. J Am Coll Nutr 2006; 25:486-492

454 Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, **Wilson PW**, Wolf PA. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006; 63(11):1545-1550.

455 Lee DS, Evans JC, Robins SJ, **Wilson PW**, Albano I, Fox CS, Wang TJ, Benjamin EJ, D'Agostino RB, Vasan RS. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007; 27:127-133

456 Scranton RE, Bozeman SR, Burton TM, Hoaglin DC, Sirko S, Hollenbeak CS, **Wilson PW**. Simple Demographic Model to Predict Multiple Cardiometabolic Risk Factors in Two Well-Known Observational Cohorts. Value Health 2007; 10:S37-S44

457 Steg PG, Bhatt DL, **Wilson PW**, D'Agostino R, Sr., Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297:1197-1206

458 Mainous AG III, Koopman RG, Diaz VA, Everett CJ, **Wilson PW**, Tilley BC. A coronary heart disease risk score based on patient-reported information. Am.J.Cardiol. 2007; 99:1236-1241

459 **Wilson PW**, Meigs, JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB, Sr. Prediction of Incident Diabetes Mellitus in Middle-aged Adults: The Framingham Offspring Study. Arch.Intern.Med. 2007; 167:1068-1074

460 Bellasi A, Lacey C, Taylor AJ, Raggi P, **Wilson PW**, Budoff MJ, Vaccarino V, Shaw LJ. Comparison of prognostic usefulness of coronary artery calcium in men versus women (results from a meta- and pooled analysis estimating all-cause mortality and coronary heart disease death or myocardial infarction). Am J Cardiol 2007; 100:409-414

461 Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, **Wilson P**F, Lackland DT, Lyons T, Jenkins AJ, Virella G. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007; 190(2):359-369

462 Abell JE, Egan BM, **Wilson PW**, Lipsitz S, Woolson RF, Lackland DT. Age and race impact the association between BMI and CVD mortality in women. Public Health Rep 2007; 122:507-512

463 Dhingra R, Gona P, Nam BH, D'Agostino RB, Sr., **Wilson PW**, Benjamin EJ, O'Donnell CJ. C-reactive protein, inflammatory conditions, and cardiovascular disease risk. Am J Med 2007; 120(12):1054-1062

464 Onufrak SJ, Bellasi A, Shaw LJ, Herzog CA, Cardarelli F, **Wilson PW**, Vaccarino V, Raggi P. Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis 2007; 199: 424-431

465 Judd SE, Nanes MS, Ziegler TR, **Wilson PW**, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2008; 87(1):136-141

466 Abell JE, Egan BM, **Wilson PW**, Lipsitz S, Woolson RF, Lackland DT. Differences in cardiovascular disease mortality associated with body mass between Black and White persons. Am J Public Health 2008; 98(1):63-66

467 Dai J, Miller AH, Bremner JD, Goldberg J, Jones L, Shallenberger L, Buckham R, Murrah NV, Veledar E, **Wilson PW**, Vaccarino V. Adherence to the mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: a twin study. Circulation 2008; 117(2):169-175 PMCID:PMC3232063
468 Rother J, Alberts MJ, Touze E, Mas JL, Hill MD, Michel P, Bhatt DL, Aichner FT, Goto S, Matsumoto M, Ohman EM, Okada Y, Uchiyama S, D'Agostino R, Hirsch AT, **Wilson PW**, Steg PG. Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry. Cerebrovasc Dis 2008; 25(4):366-374
469 Jaffa AA, Usinger WR, McHenry MB, Jaffa MA, Lipstiz SR, Lackland D, Lopes-Virella M, Luttrell LM, **Wilson PW**. Connective Tissue Growth factor and Susceptibility to Renal and Vascular Disease Risk in Type 1 Diabetes. J Clin Endocrinol Metab 2008; 93(5):1893-1900.
470 Freiberg MS, Pencina MJ, D'Agostino RB, Lanier K, **Wilson PW**, Vasan RS. BMI vs. waist circumference for identifying vascular risk. Obesity (Silver Spring) 2008; 16(2):463-469.
471 Levitzky YS, Cupples LA, Murabito JM, Kannel WB, Kiel DP, **Wilson PW**, Wolf PA, O'Donnell CJ. Prediction of intermittent claudication, ischemic stroke, and other cardiovascular disease by detection of abdominal aortic calcific deposits by plain lumbar radiographs. Am J Cardiol 2008; 101(3):326-331
472 Pearce EN, **Wilson PW**, Yang Q, Vasan RS, Braverman LE. Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort. J Clin Endocrinol Metab 2008; 93(3):888-894
473 Hivert MF, Sullivan LM, Fox CS, Nathan DM, D'Agostino RB, Sr., **Wilson PW**, Meigs JB. Associations of Adiponectin, Resistin, and TNF-alpha with Insulin Resistance. J Clin Endocrinol Metab 2008; 93: 3165-72
474 Fox CS, Pencina MJ, **Wilson PW**, Paynter NP, Vasan RS, D'Agostino RB, Sr. Lifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart Study. Diabetes Care 2008; 31: 1582-1584
475 **Wilson PW**. CETP genes, metabolic effects, and coronary disease risk. (editorial) JAMA 2008; 299(23):2795-2796.
476 Mozaffarian D, **Wilson PW**, Kannel WB. Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. Circulation 2008; 117(23):3031-3038
477 Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JE, Dube MP, Lipshultz SE, Hsue PY, Squires K, Schambelan M, **Wilson PW**, Yarasheski KE, Hadigan CM, Stein JH, Eckel RH. State of the Science Conference. Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS Executive Summary. Circulation 2008; 118: 198-210
478 **Wilson PW**, Bozeman SR, Burton TM, Hoaglin DC, Ben Joseph R, Pashos CL. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation 2008; 118(2):124-130
479 Schambelan M, **Wilson PW**, Yarasheski KE, Cade WT, Davila-Roman VG, D'Agostino RB, Sr., Helmy TA, Law M, Mondy KE, Nachman S, Peterson LR, Worm SW. Development of Appropriate Coronary Heart Disease Risk Prediction Models in HIV-Infected Patients. Circulation 2008; 118(2):198-210
480 **Wilson PW**, Umpierrez GE. Insulin resistance and pubertal changes. (editorial) J Clin Endocrinol Metab 2008; 93(7):2472-2473
481 **Wilson PW**. Cardiovascular risk assessment-where are we going? (editorial) Prev Cardiol 2008; 11(3):183-184
482 **Wilson PW**, Narayan KV. Low-cost strategies to predict cardiovascular disease. (editorial) Nat Clin Pract Cardiovasc Med 2008; 5: 518-519
483 Abell JE, Egan BM, **Wilson PW**, Lipsitz S, Woolson RF, Lackland DT. Differences in cardiovascular disease mortality associated with body mass between Black and White persons. Am J Public Health 2008; 98(1):63-66.

484 Dai J, Jones DP, Goldberg J, Ziegler TR, Bostick RM, **Wilson PW**, Manatunga AK, Shallenberger L, Jones L, Vaccarino V. Association between adherence to the Mediterranean diet and oxidative stress. Am J Clin Nutr 2008; 88(5):1364-1370.
485 Frankel DS, Meigs JB, Massaro JM, **Wilson PW**, O'Donnell CJ, D'Agostino RB, Tofler GH. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. Circulation 2008; 118(24):2533-2539.
486 Freiberg MS, Pencina MJ, D'Agostino RB, Lanier K, **Wilson PW**, Vasan RS. BMI vs. waist circumference for identifying vascular risk. Obesity (Silver Spring) 2008; 16(2):463-469.
487 Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, Uchiyama S, D'Agostino R, Ohman EM, Liau CS, Hirsch AT, Mas JL, **Wilson PW**, Corbalan R, Aichner F, Steg PG. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008; 156(5):855-863.
488 Goyal A, Nerenberg K, Gerstein HC, Umpierrez G, **Wilson PW**. Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. Diab Vasc Dis Res 2008; 5(4):276-284.
489 Judd SE, Nanes MS, Ziegler TR, **Wilson PW**, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2008; 87(1):136-141.
490 Levitzky YS, Cupples LA, Murabito JM, Kannel WB, Kiel DP, **Wilson PW**, Wolf PA, O'Donnell CJ. Prediction of intermittent claudication, ischemic stroke, and other cardiovascular disease by detection of abdominal aortic calcific deposits by plain lumbar radiographs. Am J Cardiol 2008; 101(3):326-331.
491 Lieb W, Sullivan LM, Harris TB, Roubenoff R, Benjamin EJ, Levy D, Fox CS, Wang TJ, **Wilson PW**, Kannel WB, Vasan RS. Plasma leptin levels and incidence of heart failure, cardiovascular disease and total mortality in the elderly. Diabetes Care 2009 32(4): 612-6 PMCID:PMC2660448
492 Mehta RH, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Rother J, **Wilson PW**, Richard AJ, Eagle KA, Ohman EM. Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. Eur Heart J 2008; 29(24):3052-3060.
493 Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, Manning AK, Florez JC, **Wilson PW**, D'Agostino RB, Sr., Cupples LA. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008; 359(21):2208-2219
494 Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, Satterfield S, Smith AL, Vaccarino V, Newman AB, Harris TB, **Wilson PW**, Kritchevsky SB: Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ.Heart Fail. 2008 Jul;1(2):125-33. PMCID:PMC2748334
495 Rutter MK, **Wilson PW**, Sullivan LM, Fox CS, D'Agostino RB, Sr., Meigs JB. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. Circulation 2008; 117(8):1003-1009.
496 Goyal A, Nerenberg K, Gerstein HC, Umpierrez G, **Wilson PW**. Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. Diab.Vasc.Dis.Res. 2008 Nov;5(4):276-84
497 **Wilson PW**. Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. Am J Med 2008; 121(10 Suppl 1):S15-S20.
498 **Wilson PW**, Bozeman SR, Burton TM, Hoaglin DC, Ben Joseph R, Pashos CL. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation 2008; 118(2):124-130.
499 **Wilson PW**F, Pencina M, Jacques P, Selhub J, D'Agostino R, O'Donnell CJ: C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008; 1: 92-97
500 **Wilson PW**F: Progressing from Risk Factors to Omics: Circ Cardiovas Genet: 2008; 1: 141-146

501 Chen TH, Gona P, Sutherland PA, Benjamin EJ, **Wilson PW**, Larson MG, Vasan RS, Robins SJ. Long-term C-reactive protein variability and prediction of metabolic risk. Am J Med 2009; 122(1):53-61.
502 **Wilson PW**, Narayan VKM. New York City Health and Nutrition Examination Survey: a model for urban health surveillance. Diabetes Care 2009; 32(1):204-205.
503 Brown WV, Fujioka K, **Wilson PW**, Woodworth KA. Obesity: why be concerned? Am.J.Med 2009 Apr;122(4 Suppl 1):S4-11
504 Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE, Jr., Howard BV, Howard VJ, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009 May 5;119(17):2408-16
505 Jackson D, White I, Kostis JB, Wilson AC, Folsom AR, Wu K, Chambless L, Benderly M, Goldbourt U, Willeit J, et al. Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat.Med. 2009 Apr 15;28(8):1218-37
506 Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, Psaty BM, Smith NL, Newman AB, Rodondi N, Satterfield S, Bauer DC, Bibbins-Domingo K, et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. Arch.Intern.Med. 2009 Apr 13;169(7):708-15
507 Lieb W, Sullivan LM, Harris TB, Roubenoff R, Benjamin EJ, Levy D, Fox CS, Wang TJ, **Wilson PW**, Kannel WB, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals. Diabetes Care 2009 Apr;32(4):612-6. PMCID:PMC2660448
508 Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, Grundy SM, Labarthe DR, Levy D, Rifai N, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin.Chem. 2009 Feb;55(2):378-84
509 Raz I, **Wilson PW**, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009 Mar;32(3):381-6. PMCID:PMC2646013
510 Sposito AC, Ramires JA, Jukema JW, Molina JC, Silva PM, Ghadanfar MM, **Wilson PW**. Physicians' attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions. Curr.Med.Res.Opin. 2009; 25: 1171-1178
511 Tucker AM, Vogel RA, Lincoln AE, Dunn RE, Ahrensfield DC, Allen TW, Castle LW, Heyer RA, Pellman EJ, Strollo PJ, Jr., et al. Prevalence of cardiovascular disease risk factors among National Football League players. JAMA 2009 May 27;301(20):2111-9
512 **Wilson PW**. Risk scores for prediction of coronary heart disease: an update. Endocrinol.Metab Clin.North Am 2009 Mar;38(1):33-44
513 Kalogeropoulos A, Georgiopoulou V, Harris TB, Kritchevsky SB, Bauer DC, Smith AL, Strotmeyer E, Newman AB, **Wilson PW**, Psaty BM, et al. Glycemic status and incident heart failure in elderly without history of diabetes mellitus: the health, aging, and body composition study. J.Card Fail. 2009 Sep;15(7):593-9
514 Schnabel R, Dupuis J, Larson MG, Lunetta KL, Robins SJ, Zhu Y, Rong J, Yin X, Stirnadel HA, Nelson JJ, et al. Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study. Atherosclerosis 2009 Jun;204(2):601-7
515 Weimar C, Diener HC, Alberts MJ, Steg PG, Bhatt DL, **Wilson PW**, Mas JL, Rother J. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. Stroke 2009 Feb;40(2):350-4
516 Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Rother J, Salette G, Goto S, Smith SC, Jr., Liau CS, et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur.Heart J. 2009; 30: 2318-2326

517 Butler J, Kalogeropoulos A, Georgiopoulou V, de RN, Rodondi N, Smith AL, Hoffmann U, Kanaya A, Newman AB, Kritchevsky SB, Vasan RS, **Wilson PW**, Harris TB. Serum Resistin Concentrations and Risk of New Onset Heart Failure in Older Persons. The Health, Aging, and Body Composition (Health ABC) Study. Arterioscler Thromb Vasc Biol 2009; 29: 1144-1149
518 Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, Ohman EM, Cannon CP, Eagle KA, Alberts MJ, Goto S, Smith SC, Jr., **Wilson PW**, Watson KE, Steg PG. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. Am Heart J 2009; 158(6):1038-1045.
519 Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, Grundy SM, Labarthe DR, Levy D, Rifai N, **Wilson PW**. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009; 55(2):378-384.
520 **Wilson PW**. Challenges to improve coronary heart disease risk assessment. JAMA 2009; 302(21):2369-2370.
521 **Wilson PW**. Risk scores for prediction of coronary heart disease: an update. Endocrinol Metab Clin North Am 2009; 38(1):33-44
522 Krempf M, Parhofer KG, Steg PG, Bhatt DL, Ohman EM, Rother J, Goto S, Pasquet B, **Wilson PW**. Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am.J.Cardiol. 2010 Mar 1;105(5):667-71
523 Ducrocq G, Wallace JS, Baron G, Ravaud P, Alberts MJ, **Wilson PW**, Ohman EM, Brennan DM, D'Agostino RB, Bhatt DL, et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur.Heart J. 2010; 31: 1257-1265
524 Twombly JG, Long Q, Zhu M, **Wilson PW**, Venkat NK, Fraser LA, Webber BC, Phillips LS. Diabetes care in black and white Veterans In The Southeastern United States Diabetes Care 2010; 33(5):958-63. PMCID:PMC2858198
525 Fraser LA, Twombly J, Zhu M, Long Q, Hanfelt JJ, Narayan KM, **Wilson PW**, Phillips LS. Delay in diagnosis of diabetes is not the patient's fault. Diabetes Care 2010 Jan;33(1):e10
526 Hivert MF, Sullivan LM, Shrader P, Fox CS, Nathan DM, D'Agostino RB, Sr., **Wilson PW**, Benjamin EJ, Meigs JB. The association of tumor necrosis factor alpha receptor 2 and tumor necrosis factor alpha with insulin resistance and the influence of adipose tissue biomarkers in humans. Metabolism 2010 Apr;59(4):540-6. PMCID:PMC2843788
527 Dai J, Ziegler TR, Bostick RM, Manatunga AK, Jones DP, Goldberg J, Miller A, Vogt G, **Wilson PW**, Jones L, et al. High habitual dietary {alpha}-linolenic acid intake is associated with decreased plasma soluble interleukin-6 receptor concentrations in male twins. Am.J.Clin.Nutr. 2010 May 12;
528 Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, **Wilson PW**, Schaefer EJ. Small Dense LDL Cholesterol and Coronary Heart Disease: Results from the Framingham Offspring Study. Clin.Chem. 2010; 56: 967-976
529 Kalogeropoulos A, Psaty BM, Vasan RS, Georgiopoulou V, Smith AL, Smith NL, Kritchevsky SB, **Wilson PW**, Newman AB, Harris TB, et al. Validation of the Health ABC Heart Failure Model for Incident Heart Failure Risk Prediction: The Cardiovascular Health Study. Circ.Heart Fail. 2010; 169; 708-715
530 Dai J, Lampert R, **Wilson PW**, Goldberg J, Ziegler TR, Vaccarino V. Mediterranean Dietary Pattern Is Associated With Improved Cardiac Autonomic Function Among Middle-Aged Men: A Twin Study. Circ.Cardiovasc.Qual.Outcomes. 2010; 3: 366-373
531 Rice TB, Dunn RE, Lincoln AE, Tucker AM, Vogel RA, Heyer RA, Yates AP, **Wilson PW**, Pellmen EJ, Allen TW, et al. Sleep-disordered breathing in the National Football League. Sleep 2010 Jun 1;33(6):819-24. PMCID:PMC2881715

532 Palaniappan LP, Araneta MR, Assimes TL, Barrett-Connor EL, Carnethon MR, Criqui MH, Fung GL, Narayan KM, Patel H, Taylor-Piliae RE, et al. Call to Action: Cardiovascular Disease in Asian Americans. A Science Advisory From the American Heart Association. Circulation 2010; 122: 1242-1252
533 Goyal A, Norton CR, Thomas TN, Davis RL, Butler J, Ashok V, Zhao L, Vaccarino V, **Wilson PW**. Predictors of Incident Heart Failure in a Large Insured Population: A One Million Person-Year Follow-up Study. Circ.Heart Fail. 2010; 3: 698-705
534 Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, **Wilson PW**, Alberts MJ, D'Agostino R, Liau CS, et al. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. JAMA 2010; 304: 1350-1357
535 **Wilson PW**. Preface-Global impact of the Framingham Heart Study. Prog.Cardiovasc.Dis. 2010 Jul;53(1):3
536 **Wilson PW**. Improving the landscape for prevention. Prev.Cardiol. 2010;13(3):145
537 Le NA, **Wilson PW**. How Do We Find the Best Biomarkers for Cardiovascular Disease? Clin Chem 2010; 56: 1658-1659
538 Otokozawa S, Ai M, Asztalos BF, White CC, Demissie-Banjaw S, Cupples LA, Nakajima K, **Wilson PW**, Schaefer EJ. Direct assessment of plasma low density lipoprotein and high density lipoprotein cholesterol levels and coronary heart disease: Results from the Framingham Offspring Study. Atherosclerosis 2010; 213: 251-255
539 Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, **Wilson PW**, Kirkman MS. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694-2701
540 Roussel R, Travert F, Pasquet B, **Wilson PW**, Smith SC, Jr., Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170(21):1892-1899
541 Shaw LJ, **Wilson PW**, Hachamovitch R, Hendel RC, Borges-Neto S, Berman DS. Improved Near-Term Coronary Artery Disease Risk Classification With Gated Stress Myocardial Perfusion SPECT. JACC Cardiovasc Imaging 2010; 3(11):1139-1148.
542 Twombly JG, Long Q, Zhu M, Fraser LA, Olson DE, **Wilson PW**, Narayan KM, Phillips LS. Validity of the primary care diagnosis of diabetes in veterans in the southeastern United States. Diabetes Res Clin Pract 2010.
543 Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, **Wilson PW**, Woo YJ. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association. Circulation 2011; 123: 933-944
544 Hivert MF, Sullivan LM, Shrader P, Fox CS, Nathan DM, D'Agostino RB, Sr., **Wilson PW**, Kowall B, Herder C, Meisinger C, Thorand B, Rathmann W, Meigs JB. Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study. Diabetologia 2011; 54: 1019-1024
545 Shara NM, Wang H, Valaitis E, Pehlivanova M, Carter EA, Resnick HE, Wang W, Umans JG, Lee ET, Howard BV, Devereux RB, **Wilson PW**. Comparison of estimated glomerular filtration rates and albuminuria in predicting risk of coronary heart disease in a population with high prevalence of diabetes mellitus and renal disease. Am J Cardiol 2011; 107(3):399-405.
546 **Wilson PW**. Prediction of cardiovascular disease events. Cardiol Clin 2011; 29(1):1-13.
547 **Wilson PW**, D'Agostino RB, Fox CS, Sullivan LM, Meigs JB. Type 2 diabetes risk in persons with dysglycemia: The Framingham Offspring Study. Diabetes Res Clin Pract 2011; 92: 124-127

548 Ai M, Otokozawa S, Asztalos BF, White CC, Cupples LA, Nakajima K, Lamon-Fava S, **Wilson PW**, Matsuzawa Y, Schaefer EJ. Adiponectin: An independent risk factor for coronary heart disease in men in the Framingham offspring Study. Atherosclerosis 2011 Aug;217(2):543-8
549 Bidulescu A, Liu J, Musani SK, Fox ER, Samdarshi TE, Sarpong DF, Vaccarino V, **Wilson PW**, Arnett DK, Din-Dzietham R, et al. Association of Adiponectin with Left Ventricular Mass in African Americans: The Jackson Heart Study. Circ.Heart Fail. 2011; 4: 747-753
550 **Wilson PW**. Remembering William B. Kannel, MD, MPH (1923-2011). J.Clin.Lipidol. 2011 Nov;5(6):501-2
551 Bukowski R, Davis KE, **Wilson PW**. Delivery of a small for gestational age infant and greater maternal risk of ischemic heart disease. PLoS.ONE. 2012;7(3):e33047. PMCID:PMC3303879
552 Dallongeville J, Bhatt DL, Steg PH, Ravaud P, **Wilson PW**, Eagle KA, Goto S, Mas JL, Montalescot G. Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry. Eur.J.Prev.Cardiol. 2012 Apr;19(2):241-9
553 Rodondi N, Locatelli I, Aujesky D, Butler J, Vittinghoff E, Simonsick E, Satterfield S, Newman AB, **Wilson PW**, Pletcher MJ, et al. Framingham risk score and alternatives for prediction of coronary heart disease in older adults. PLoS.ONE. 2012;7(3):e34287. PMCID:PMC3314613
554 Roussel R, Hadjadj S, Pasquet B, **Wilson PW**, Smith SC, Jr., Goto S, Tubach F, Marre M, Porath A, Krempf M, et al. Thiazolidinedione use is not associated with worse cardiovascular outcomes: A study in 28,332 high risk patients with diabetes in routine clinical practice: Brief title: Thiazolidinedione use and mortality. Int.J.Cardiol. 2012 May 4;
555 Vesper HW, **Wilson PW**, Rifai N. A message from the laboratory community to the National Cholesterol Education Program Adult Treatment Panel IV. Clin.Chem. 2012 Mar;58(3):523-7
556 **Wilson PW**, D'Agostino R, Sr., Bhatt DL, Eagle K, Pencina MJ, Smith SC, Alberts MJ, Dallongeville J, Goto S, Hirsch AT, et al. An international model to predict recurrent cardiovascular disease. Am.J.Med 2012 Jul;125(7):695-703
557 Gaziano JM, **Wilson PW**. Cardiovascular risk assessment in the 21st century. JAMA 2012 Aug 22;308(8):816-7
558 **Wilson PW**. Insulin resistance and ischemic myocardial injury post-percutaneous coronary interventions. JACC.Cardiovasc.Interv. 2012 Nov;5(11):1168-9
559 Eapen DJ, Manocha P, Patel RS, Hammadah M, Veledar E, Wassel C, Nanjundappa RA, Sikora S, Malayter D, **Wilson PW**, et al. Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. J Am.Coll.Cardiol. 2013 Jul 23;62(4):329-37
560 Bukowski R, Davis KE, **Wilson PW**. Delivery of a small for gestational age infant and greater maternal risk of ischemic heart disease. PLoS.ONE. 2012;7(3):e33047. PMCID:PMC3303879
561 Dallongeville J, Bhatt DL, Steg PH, Ravaud P, **Wilson PW**, Eagle KA, Goto S, Mas JL, Montalescot G. Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry. Eur.J.Prev.Cardiol. 2012 Apr;19(2):241-9
562 Le NA, Jin R, Tomassini JE, Tershakovec AM, Neff DR, **Wilson PW**. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients. J Am.Heart Assoc. 2013;2(4):e000037
563 Ridker PM, **Wilson PW**. A trial-based approach to statin guidelines. JAMA 2013 Sep 18;310(11):1123-4
564 Udell JA, Steg PG, Scirica BM, Eagle KA, Ohman EM, Goto S, Alsheikh-Ali AA, Porath A, Corbalan R, Umez-Eronini AA, **Wilson PW** et al. Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. Eur.J Prev.Cardiol. 2013 Aug 5
565 Le NA, Farkas-Epperson M, Sweeney ME, **Wilson PW**, Virgil BW. Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome. Atherosclerosis 2013 Dec;231(2):268-73

566 Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Sr., Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson J, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, **Wilson PW**: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 Nov 12; also in J.Am.Coll.Cardiol. 2013 Nov 12

567 Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, **Wilson PW**: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 Nov 12; also in J.Am.Coll.Cardiol. 2013 Nov 7;